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ABSTRACT 
The epidermal growth factor receptor (EGFR) is a major tyrosine kinase that is responsible 
for cell growth, differentiation and proliferation in human bodies. EGFR overexpression has 
been detected in various cancer cell lines. Hence, EGFR has been validated as a potential 
target for anti-cancer treatment. Monoclonal antibodies (MAbs) and tyrosine kinase inhibitors 
(TKIs) have been developed for EGFR inhibition. EGFR-TKIs have been found to be the 
most promising inhibitors, and hence there have been major research efforts towards their 
development. Gefitinib and erlotinib are first generation reversible EGFR-TKIs, but their main 
drawback is the development of drug resistance due to the T790M mutation. Afatinib is a 
second generation covalent irreversible EGFR-TKI that is active against the T790M mutant, 
however, it has a narrow therapeutic window that introduces severe side effects. Recently, 
covalent reversible EGFR-TKIs have been developed using various strategies: the use of the 
cyanoacrylate group as the active warhead is one strategy that is currently under 
development. 
In this project we aimed to synthesise anilino-pyrimidine ketoamides and ketoesters as a 
novel series of covalent reversible EGFR-TKIs. In the first part of this project eight anilino-
pyrimidine ketoamides were synthesised. Starting from 4,6-dichloropyrimidine a nucleophilic 
displacement of one chloro group was performed using monoprotected diethylene glycol 
yielding 4-chloro-6-{2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethoxy}pyrimidine. As a key 
step, an acid catalysed amination reaction was used to couple the functionalised pyrimidine 
with eight different aniline substrates. Using 3-bromoaniline as an example, this reaction 
yielded 2-{2-[4-(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy}ethanol as an intermediate. 
After successful synthesis of the key intermediate, the hydroxy group was oxidised using 2-
iodoxybenzoic acid (IBX) to afford 2-{2-[4-(3-bromophenylamino)pyrimidin-6-
yloxy]ethoxy}acetaldehyde. The Passerini reaction was then used to convert the aldehyde to 
an α-hydroxy amide functionality, thereby forming 2-hydroxy-N-isopropyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanamide. Finally, the α-hydroxy amide 
system was oxidised using IBX to afford the desired α-ketoamide system, thereby 
completing the synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3-bromophenylamino)pyrimidin-6-
yloxy]ethoxy}propanamide and seven analogues.  
In the second part of this project, a similar synthetic approach was utilised in an attempt to 
synthesise anilino-pyrimidine ketoesters. Starting from 2-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}acetaldehyde; potassium cyanide was used to 
prepare 2-hydroxy-3-{2-[4-(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanenitrile. 
Functional group conversion from the cyanohydrin to α-hydroxy ester was attempted using 
vii 
 
methanol in an acidic medium but, unfortunately, an unexpected product was obtained. 
Instead of affording an α-hydroxy ester system, from this reaction we isolated an acetal of 
the original aldehyde. Unfortunately, the unsuccessful attempt to synthesise methyl-3-{2-[4-
(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy}-2-hydroxypropanoate prevented further 
progress towards the synthesis of the targeted methyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}-2-oxopropanoate. 
A selection of the anilino-pyrimidine analogues were screened for anticancer activity in an in 
vitro MTT assay using five different cell lines. From the preliminary results, 2-{2-[4-(3-chloro-
4-fluorophenylamino)pyrimidin-6-yloxy]ethoxy}acetaldehyde was the only active compound 
with an IC50 = 48.74 μM against the MCF7 breast cancer cell line and an IC50 = 30.75 μM 
against the SF268 glioblastoma cell line.  
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CHAPTER 1: Epidermal Growth Factor Receptor in Non-Small Cell Lung 
Cancer 
1.1. Introduction 
Enzymes are macromolecular catalysts for biochemical reactions. Enzymes regulate most of 
the biological processes that occur within living organisms. Most enzymes are proteins, 
although a few are catalytic RNA molecules.1  
Kinases are enzymes that belong to the transferase class; these enzymes are responsible 
for a reversible covalent process in cells known as phosphorylation.2 This process is a 
transfer of phosphate groups from phosphate donating molecules such as adenosine 
triphosphate (ATP) to individual substrates.2 There are three types of substrates that kinases 
can act upon: protein substrates, carbohydrate substrates and lipid substrates; and they are 
classified depending on their specific substrates.2 Protein kinases phosphorylate proteins on 
their histidine, tyrosine, threonine or serine amino acids. Protein kinases often act on more 
than one amino acid and the amino acid substrates can regulate activity for more than one 
kinase.2 Hence, protein kinases are classified into two broad classes depending on what 
controls their activity: serine-threonine protein kinases and tyrosine-specific protein kinases.2 
Tyrosine kinases (TKs) are one of the most important kinase families as regards to cancer 
biology.3 There are 90 distinct tyrosine kinases found in humans, which have been broadly 
classified into 58 receptor tyrosine kinases (RTKs) and 32 non-receptor tyrosine kinases 
(NRTKs).3 The main difference between RTKs and NRTKs is in their structural domain 
organisation. RTKs exist on the cell membrane as part of the cell surface while NRTKs are 
cytoplasmic enzymes, meaning that they are located inside the cell. The RTK structural 
domain is made up of two subdomains; the N-terminal and C-terminal subdomain. These 
two subdomains make up three regions of RTKs; the extracellular region, the 
transmembrane region and the intracellular region (Figure 1.1).22 As suggested by the group 
name, NRTKs don’t have receptor-like features and they lack the extracellular and the 
transmembrane regions. NRTKs are said to be intracellular since they are restricted to the 
cytoplasm (intracellular region) and don’t have direct interaction with extracellular ligands.2 
Previous studies have demonstrated strong evidence regarding the involvement of TKs in 
cancer. Previous results have demonstrated an intimate relationship between abnormal cell 
signal transduction of the TKs and the initiation and progression of a variety of human 
cancers.2,3,4 Hence, RTKs and NRTKs both present themselves as potential drug targets for 
the treatment of certain cancer types. Intensive research has focused on the development of 
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RTK inhibitors for cancer treatment, mainly because the evidence linking these receptors 
with certain types of human cancers is the most substantial.2 
 
 
Figure 1.1: Structural domains of RTKs. Shown are the extracellular ligand binding domain, the 
transmembrane domain and the intracellular tyrosine kinase domain. The signalling pathways that are 
activated upon specific ligand binding are also indicated. Abbreviations: ERK: extracellular-regulated 
kinase; JAK:  janus kinase; P: phosphorylated tyrosine residue; PI3 kinase: phosphatidylinositol-3 
kinase; Grb 2: Growth factor receptor bound protein2; Src: rous sarcoma oncogene cellular homolog; 
Shc: SH2-containing collagen-related proteins;  PLC: phospholipase C; STAT: signal transducer and 
activator of transcription .22   
Transmembrane domain 
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RTKs are cell-surface transmembrane receptors which have been widely studied, mainly 
because of their particular significance to cancer. The 58 RTKs have been classified into 20 
subfamilies.3,22 Platelet-derived growth factor (PDGFR), fibroblast growth factor receptor 
(FGFR), epidermal growth factor receptor (EGFR) and insulin receptor families are some of 
the 20 RTK subfamilies.2 These receptors mediate critical functions in signal transduction 
processes, transducing signals from various ligands of the extracellular environment to 
different intracellular signalling pathways.3,15 Epidermal growth factor (EGF), fibroblast 
growth factor (FGF), nerve growth factor (NGF) and vascular endothelial growth factor 
(VEGF) are some examples of the extracellular ligands that bind to the receptors.2,3,12,15 The 
biological processes facilitated by RTKs include: cell proliferation, differentiation, migration, 
metabolism and apoptosis.15 Extensive understanding of all parts of the signal transduction 
process is critical, mainly because it gives better understanding of the cause of cancer and 
its potential treatments.  
The first RTK subfamily to be associated with cancer was the EGFR/ERBB family.3 The 
EGFR/ERBB subfamily consists of four closely related RTKs, which include EGFR (ERBB1), 
HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4).3,8 Although these RTKs have a 
similar basic structure they each have distinct properties, including the difference observed 
in their tyrosine kinase activity. EGFR is a 53 amino acid-containing RTK that acts primarily 
as a growth factor receptor and in downstream signalling from growth factor activation.  As is 
the case for most RTKs, EGFR is a transmembrane protein that is activated by the binding 
of its specific growth factor ligand. EGFR inactive monomer consists of the extracellular 
ligand binding domain, the single transmembrane portion and the intracellular tyrosine 
kinase domain that resides within the cytoplasm and regulates signalling pathways to control 
cellular proliferation.8 
Upon binding to the EGF ligand, EGFR transitions from an inactive monomer to an active 
homodimer or heterodimer with other EGFR/ERBB family members. As a result, 
autophosphorylation of the intracellular tyrosine domain occurs initiating several signal 
transduction pathways (Figure 1.1). The major pathways include the Ras-Raf-mitogen 
activated protein kinase (Ras-Ref-MEPK-ERK) pathway which controls cell growth, 
proliferation, apoptosis and cell survival; the phosphatidylinositol-3-kinase (PI3K/AKT) 
pathway which stimulates cell proliferation and growth and  inhibition of apoptosis; and the 
janus kinase (JAK-STAT) pathway which induces gene transcription and protein 
translation.2,3,8,22  In normal cells, activation of the EGFR signaling pathways is under 
regulated physiological control; however, irregular activation of these pathways can lead to 
uncontrollable cell growth, which leads to cancer.3,8  
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Irregular activation of EGFR can be a result of mutational activation of the receptor or 
receptor/ligand overexpression. As a result of the irregular EGFR activation, strongly 
enhanced signaling capacity of the kinase is observed which then leads to malignant 
transformation. This dysregulation has been observed in 43-89% of non-small cell lung 
cancer cases.3,4,8 Since this discovery extensive research has focused on designing 
therapeutic strategies to inhibit EGFR. One such method is the use of epidermal growth 
factor receptor tyrosine kinase inhibitors (EGFR-TKIs). EGFR-TKIs are low molecular weight 
drugs that bind to the ATP binding site, thus inhibiting EGFR tyrosine phosphorylation and in 
turn inhibiting lung cancer.15 
1.2. Lung cancer 
Lung cancer is one of the deadliest types of cancer for both men and women worldwide. 
According to the WHO cancer fact sheet, in 2015 lung cancer was the most common cause 
of cancer deaths worldwide. Lung cancer was responsible for 1.7 million of the 8.8 million 
observed cancer deaths.10 About 80% of lung cancer deaths are caused by tobacco 
smoking.6,7,10 Although tobacco smoking is the major risk factor for lung cancer, not all 
smokers get lung cancer and not all lung cancer deaths are due to tobacco smoking. Other 
risk factors include passive smoking, ultraviolet and ionizing radiation, and chemical 
carcinogens such as asbestos and arsenic.7  
The two types of primary lung cancer are the less common small-cell lung cancer (SCLC) 
and the most common non-small-cell lung cancer (NSCLC) which is made up of three 
subtypes; squamous cell carcinoma, adenocarcinoma and large-cell carcinoma. The major 
differences between the two types of lung cancer are in their biology, therapeutic 
approaches and outcomes. SCLC accounts for about 15% of the reported lung cancer cases 
and of all cancer patients, patients with SCLC express the most malignancy.32 This type of 
lung cancer is broadly divided into two groups; the classic and the variant type. The variant 
subtype expresses poor chemotherapy response as compared to the classic subtype, hence 
it has shorter survival time.28 SCLC generally spreads to other organs quicker than NSCLC. 
Additionally, the growth fraction and cell replication time of SCLC is much more rapid than 
that of NSCLC.30   
NSCLC accounts for about 85% of the lung cancer cases diagnosed every year.9 Studies of 
NSCLC cell lines have detected the overexpression of EGFR in 43-89% cases.4,8 During a 
study of the in vitro biological behaviour of the NSCLC, a high concentration of EGFR was 
detected on the cell surfaces of the NSCLC cell lines.4 The observed overexpression of 
EGFR in NSCLC suggested EGFR as a novel potential target for lung cancer treatment. As 
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previously stated, this observation then led to the development of EGFR-TKIs, amongst 
other cancer therapeutics, as potential drugs for the treatment of NSCLC. 
1.3. EGFR as a drug target for NSCLC treatment 
EGFR overexpression or deregulation in NSCLC has prompted the development of EGFR 
inhibitors for NSCLC treatment. Like any other RTK, EGFR can be viewed as a multisite 
drug target. The extracellular ligand binding domain, intracellular tyrosine kinase domain and 
the transmembrane domain have all been identified as potential targets for drug 
development, and they have been investigated in a number of experimental studies.15,22 
Monoclonal antibodies, small organic molecules, antisense oligonucleotides, and 
peptidomimetics are some of the strategies that have been explored for kinase 
inhibition.3,15,22 Monoclonal antibodies and small organic molecules are two main approaches 
that have been used for cancer therapeutics.3,16  
Monoclonal antibodies are employed for EGFR inhibition by targeting the extracellular 
domain, blocking ligand binding and/or receptor activation which consequently obstructs 
EGF dependent cell proliferation. Several EGFR antibodies have advanced in clinical studies 
and cetuximab is one of the FDA approved drugs.3 Cetuximab directly binds to EGFR with 
high affinity and therefore blocks ligand-induced EGFR autophosphorylation. Cetuximab was 
approved by the FDA for the treatment of colorectal cancer and head and neck cancer.3,16 
Cetuximab has also been used in combination with other chemotherapeutic treatments 
against advanced NSCLC and increased anti-tumour effects were observed.16 Despite the 
effectiveness observed with the use of cetuximab, a number of factors have been observed 
that make its development and use troublesome. Monoclonal antibodies such as cetuximab 
require relatively costly complex processes for their production while small organic 
molecules are produced by simpler organic synthesis methods. Furthermore, monoclonal 
antibodies are intravenously administered which is a more difficult administration process as 
compared to the orally available small organic molecules.16 One particularly promising 
approach is the use of small organic molecules which are ATP-competitive inhibitors.  
ATP-competitive EGFR-TKIs bind to the ATP binding site which is situated on the 
intracellular domain of EGFR and compete with ATP for binding.  This attenuates the cell 
signalling pathway that would normally induce tumour cell proliferation and division. All of the 
currently used EGFR-TKIs are ATP-competitive inhibitors, meaning that they interfere with 
the intracellular EGFR kinase domain. Quinazolines, pyridopyrimidines and 
pyrrolopyrimidines are some of the most promising EGFR-TKIs. In addition to the already 
mentioned advantages of using small organic molecules, one hypothesised advantage of 
ATP-competitive EGFR-TKIs was the development of highly selective inhibitors; the high 
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selectivity was hypothesised to be due to the highly conserved ATP-binding site.3 The ATP-
binding site has been identified as a promising target for NSCLC treatment and this has 
been confirmed by the advanced widespread use of several ATP-competitive EGFR-TKIs. 
Gefitinib, erlotinib and afatinib are some examples of the ATP-competitive FDA approved 
EGFR-TKIs that are currently on the market for the treatment of NSCLC and these will be 
discussed in detail in subsequent sections.23 
1.3.1. The ATP binding site 
The ATP binding site is conserved within the intracellular tyrosine kinase domain (Figure 
1.1). The structural features of the ATP binding cleft include the adenine region, the sugar 
region, the hydrophobic channel and the phosphate binding region (Figure 1.2).3,15  
 
 
Figure 1.2: Overview of the ATP binding site of protein kinases.15 The protein is shown in black and 
the ATP molecule is shown in red. 
As seen in Figure 1.2, ATP has various interactions with the different regions of its binding 
pocket. The adenine region interacts with the backbone amides in the hinge region (NH and 
C=O functionalities) via hydrogen bonding. These hydrogen bond interactions have been 
observed as being the most important interactions as regards to the binding of ATP 
competitive inhibitors.3,15 Directly attached to the adenine region is the sugar region and 
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although this region is not significantly used by ATP it does play a crucial role in inhibitor 
selectivity.15 The phosphate binding region is also not particularly significant for ATP binding, 
but it can be used to improve inhibitor selectivity.15 The last important structural region 
observed in the ATP binding cleft is the hydrophobic pocket. When ATP is bound to the 
active site, the hydrophobic region is blocked off. At the entrance of the hydrophobic pocket 
lies a gatekeeper residue. The gatekeeper residue is situated on the N-terminal side of the 
linker region, controlling access to the hydrophobic pocket.3,34 The gatekeeper residue is the 
threonine 790 amino acid and its side chain is important in drug design as it helps with the 
specificity of the kinase towards inhibitors.3,34  
1.3.2. First generation EGFR-TKIs  
1.3.2.1. Erlotinib and gefitinib 
First generation EGFR-TKIs are low molecular weight quinazoline derivatives that selectively 
and reversibly bind in the ATP binding pocket, competing with ATP (Figure 1.3).18 These 
orally administered drugs have been shown to be effective against both the wild-type and 
some mutant EGFR.23 
  
Figure 1.3: Chemical structures of the anilino-quinazoline based first generation EGFR-TKIs used for 
the treatment of NSCLC.   
Upon successful binding of these drugs in the ATP pocket, autophosphorylation of EGFR is 
inhibited, which in turn inhibits the activation of the downstream signalling pathways of 
EGFR hence inhibiting the replication of malignant cells resulting in apoptosis.  
During phase II clinical trials, both gefitinib (1) and erlotinib (2) showed antitumour 
activity.23,24 Gefitinib was initially approved in May 2003 as monotherapy for locally advanced 
and metastatic NSCLC. After the approval, the FDA then requested post marketing studies 
to investigate the efficacy of gefitinib.25 At that time, docetaxel was FDA approved as 
second-line treatment of advanced NSCLC for chemo-naïve patients. A study that evaluated 
the efficacy of gefitinib against docetaxel indicated that there was no significant difference in 
the survival benefit between the two drugs.25,27  Results from another study that evaluated 
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gefitinib survival in lung cancer (ISEL) indicated that the drug showed no significant increase 
in the overall survival when compared to placebo.26 Based on the ISEL trial results, in June 
2005 the FDA approval was amended, limiting gefitinib distribution and application to 
patients who were currently benefiting, or had benefited from gefitinib monotherapy.25 
Erlotinib was approved by the FDA in November 2004 as monotherapy for second or third-
line treatment of chemotherapy resistant advanced NSCLC.18 Phase I trial studies had 
recommended a daily dose of 150 mg/d on a continuous uninterrupted program.31 To 
investigate whether erlotinib prolonged overall survival, a phase III clinical trial study was 
conducted that evaluated the recommended 150 mg/d dose of erlotinib against placebo in 
chemotherapy resistant NSCLC. The obtained results indicated that erlotinib increased the 
overall survival by 2 months; it was 6.7 months for the erlotinib group and 4.7 months for the 
placebo group.28 Additionally, it was observed that patients with EGFR positive tumour cells 
had a higher rate of response.28,31 Also, this trial study indicated superiority for erlotinib as 
compared to the results obtained for gefitinib in a similar study.26,28 However, this might not 
directly mean that erlotinib is superior to gefitinib, it could possibly be an effect of different 
characteristics between the patients in the two trial studies.  
Subsequent studies then reported that NSCLC patients with somatic EGFR mutations 
showed increased clinical response as compared to the wild-type EGFR when treated with 
both erlotinib and gefitinib.18,24  Further studies then reported an interesting aspect that 
tumours with EGFR-activating mutations completely relied on EGFR for the activation of the 
downstream signalling pathways which regulates their survival.8,23 This then meant that 
EGFR inhibition would result in apoptosis of the cancer cells. The most commonly observed 
EGFR mutations are the exon 19 deletion and the L858R point mutation.23,24 The 
implications of the increased clinical response of EGFR-mutant NSCLC patients and the 
increased knowledge about EGFR mutations in NSCLC patients allowed for further 
developments in the use EGFR-TKIs for NSCLC treatment.25  
New trial studies were done targeting NSCLC patients with somatic EGFR mutations. A 
phase III multicentre, open-label, randomised trial was done investigating the efficacy of 
erlotinib against platinum based chemotherapy in EGFR-mutant patients. The results 
indicated superiority for erlotinib as regards to the progression free survival; it was 9.7 
months for the erlotinib treated patients and 5.2 months for the chemotherapy based 
patients.23,33 The overall survival was 19.3 months for the erlotinib group and 19.5 months for 
the chemotherapy group, showing that no significant difference was observed. Based on this 
trial study, erlotinib was then FDA-approved in May 2013 as first-line treatment for EGFR-
mutated NSCLC patients.33 A similar phase III trial study was conducted for gefitinib and it 
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was then reapproved by the FDA in July 2015.23,25 Gefitinib indicated increased progression 
free survival when compared to chemotherapy during the treatment of EGFR-mutated 
NSCLC patients, providing an additional first-line treatment option for this group of patients.25 
Despite the observed clinical activity of erlotinib and gefitinib, over time patients acquired 
resistance towards these drugs hence making them ineffective. The acquired resistance was 
normally observed after a median of 14 months.23 For further developments in search for 
more effective NSCLC treatments a better understanding behind the observed resistance 
was required.  
1.3.2.2. The binding mode of the first generation EGFR-TKIs 
Erlotinib and gefitinib both have similar binding modes in the ATP binding pocket.49 From 
Figure 1.3 it is important to note that the quinazoline core of the inhibitors mimics the 
adenine functionality of the natural ATP substrate. Thus, as the adenine ring forms hydrogen 
bonds with the back bone amides in the hinge region (Figure 1.2), the same interactions are 
observed between the quinazoline core of gefitinib and the main amide chain of M793 in the 
hinge region (Figure 1.4).49  
 
 
Figure 1.4: Gefitinib binding mode in ATP binding pocket of the wild type EGFR.49 
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One other important interaction between the inhibitor and the active site is that of the aniline 
moiety. As can be seen in Figure 1.4 the 3-chloro-4-fluoro aniline probes the hydrophobic 
pocket of the active site. Successful probing of the hydrophobic pocket is only possible when 
the amino acid side chain is small, for example threonine (T790 in this case), as this results 
in effective binding while a bulky methionine group would induce steric hindrance.24,49  
1.3.2.3. Mechanism of acquired resistance to erlotinib and gefitinib  
Of the multiple identified mechanisms that result in the observed erlotinib and gefitinib 
resistance, most mechanisms have been identified to be secondary mutations.34 The T790M 
mutation is one of the most commonly identified secondary mutations that results in the 
ineffectiveness of the first generation EGFR-TKIs.23 About 50-60% of tumours in patients 
that developed resistance to erlotinib and gefitinib were found to have the T790M mutation.23  
Threonine 790 is an amino acid commonly known as the gatekeeper residue. It resides in 
the hydrophobic pocket of the ATP binding site and it has been thought of as a determinant 
of the specificity of ATP-competitive EGFR-TKIs.3,34 The T790M mutation is a result of the 
substitution of the threonine amino acid by the bulky methionine amino acid. The bulky 
methionine was hypothesised to inhibit the activity of erlotinib and gefitinib by sterically 
hindering their binding into the ATP hydrophobic pocket.24 The T790M mutation was shown 
to increase the affinity of EGFR to natural ATP, resulting in the loss of efficacy of the first 
generation drugs as they compete with ATP. Although the exact mechanism by which the 
T790M mutation results in the observed resistance is not fully understood, the inhibition 
through steric hindrance hypothesis doesn’t quite make sense as structurally similar 
irreversible EGFR-TKIs remain active in vitro even when the T790M mutation is observed. It 
is thought that the irreversible EGFR-TKIs retain their anti-cancer activity through covalently 
binding in the ATP pocket. The covalent binding eliminates the competition of existing in 
reverse equilibrium with the natural ATP substrate, hence they remain active.23,24 This class 
of irreversible inhibitors is known as the second generation EGFR-TKIs.  
1.3.3. The way forward: second generation EGFR-TKIs  
The next approach was to develop EGFR inhibitors that would exhibit activity against 
multiple targets and form irreversible covalent bonds with the targeted active site.35 Second 
generation EGFR-TKIs are also anilino-quinazoline or quinolone derivatives like erlotinib and 
gefitinib. Chemical modification of erlotinib and gefitinib offered new drug discovery 
possibilities, the presence of a Michael acceptor in the second generation drugs allowed for 
the formation of an irreversible covalent bond in the active site. Various second generation 
drugs have been developed over the past years, but Afatinib (3, Figure 1.5) remains the 
most promising drug.9 With the exception of the formation of a covalent bond, the binding 
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mode interactions between afatinib and the active site are similar to the ones observed for 
gefitinib.34  
                       
                                      A                                                                                                       B 
Figure 1.5: A. Chemical structure of the anilino-quinazoline based second generation EGFR-TKI, 
Afatinib, used for the treatment of NSCLC. B. The main covalent bond interaction (highlighted in red), 
between afatinib and the Cys797 residue in the ATP binding pocket of EGFR.38 
The most prominent structural difference observed between the first generation EGFR-TKIs 
and afatinib is the presence of the reactive acrylamide group in afatinib (Figure 1.5A). The 
acrylamide functionality (Michael acceptor) allows for the formation of a covalent bond with 
the cysteine residue (Figure 1.5B).  Afatinib is a dual EGFR/HER2 inhibitor that selectively, 
irreversibly and covalently binds to the Cys797 residue in the tyrosine kinase catalytic 
domain hence inhibiting its activity.35,38 Since afatinib forms irreversible covalent bonds in the 
ATP binding site this allows for longer inhibition time of the EGFR tyrosine activity: afatinib 
completely inhibits EGFR until new receptors are synthesised.35  
Initially, afatinib was considered as a potential candidate to overcome the T790M mutation 
since it had been confirmed to be a more potent inhibitor of mutant T790M EGFR in vitro 
than the first generation EGFR-TKIs.9,23 Clinical studies revealed that afatinib was equally 
potent against the wild type and mutant T790M EGFR, and it was reported that there was 
significant inhibition observed with this drug towards the mutant T790M EGFR.38 Toxicity 
was reported to be the main limitation of effective inhibition.38 The recommended afatinib 
dosage for the inhibition of the wild type EGFR wasn’t effective against the mutant T790M 
EGFR, the main drawback was that higher dosages were associated with side effects.37,38 
The most commonly observed side effects were gastrointestinal e.g. diarrhoea and vomiting; 
and cutaneous e.g. acne and rash.9,23,38 Other second generation EGFR-TKIs include, 
dacomitinib, neratinib, carnetinib and pelitinib.38 However, the main drawback of all the 
second generation drugs is that they contain the very reactive acrylamide functionality, which 
was believed to come with the toxicity burden. Hence new developments were still required 
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to find molecules that enhanced activity while limiting the observed toxicities.38 Essentially 
the ideal drug would have to inhibit the mutant T790M EGFR and the wild type EGFR 
without severe toxicities. 
1.3.4. Overcoming toxicity limitations: third generation EGFR-TKIs 
Recently a new class of EGFR-TKIs has been under investigation and most compounds 
from this class are currently under clinical development. Like the second generation EGFR-
TKIs, the third generation EGFR-TKIs bind covalently in the ATP binding pocket of EGFR. 
Research has shown that covalent binding of the tyrosine kinase inhibitors to the EGFR is 
required in order to overcome the observed T790M gatekeeper mutation, hence the third 
generation EGFR-TKIs still contain the Michael acceptor functionality which allows for the 
covalent binding of the Cys797 residue.38 Interestingly, however, the third generation EGFR-
TKIs seem to selectively inhibit the mutant T790M EGFR, while having much less activity 
against the wild type EGFR.38 Since this generation of small molecule inhibitors have very 
low inhibitory effect against the wild type EGFR, that eliminates the toxicity limitation 
observed with the second generation EGFR-TKIs.38,39 
Third generation EGFR-TKIs are orally available amino pyrimidine based derivatives (Figure 
1.6). Several members of this class of EGFR-TKIs have been developed, but most of them 
have not yet progressed to clinical trials. Osimertinib (4), olmutinib (5) and rociletinib (6) are 
a few molecules that have been extensively studied and have even progressed to clinical 
trials.38,39 WZ4002 (7) is one other small molecule inhibitor that has been widely studied 
although it hasn’t progressed to human clinical trials.39  
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Figure 1.6: Chemical structures of the amino pyrimidine based third generation EGFR-TKIs. 
Osimertinib (4) is the only FDA approved molecule for the treatment of NSCLC patients with mutant 
T790M EGFR.40 
1.3.4.1. Osimertinib 
Osimertinib (4) is an orally available mono-anilino pyrimidine third generation EGFR-TKI. 
Osimertinib forms an irreversible covalent bond with the Cys797 residue in the ATP binding 
pocket.40 Unlike the second generation EGFR-TKIs, osimertinib only selectively inhibits the 
mutant positive EGFR, having very low activity towards the wild type EGFR.39,40 Osimertinib 
is characterized by the pyrimidine scaffold, different from the first and second generation 
quinazoline scaffold, thus it takes a different orientation in the active site.52 Unlike the second 
generation EGFR-TKIs, osimertinib doesn’t need to be inside the back hydrophobic pocket 
for effective inhibition (Figure 1.7). That is, the bulky methionine amino acid chain that is a 
result of the T790M mutation doesn’t affect its activity.38 
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Figure 1.7: Osimertinib (4) binding mode in ATP binding pocket of EGFR.38 
From Figure 1.7 above it is important to note the different binding mode of osimertinib as 
compared to the explained binding mode of the first and second generation drugs. In the 
binding mode of first and second generation drugs, the aniline moiety binds into the back 
hydrophobic pocket of the ATP binding site and the gatekeeper residue has been shown to 
have an effect on the observed resistance of mostly the first generation drugs.24 However, 
osimertinib is observed to lack that aniline moiety that needs to probe the hydrophobic 
pocket. Instead it has an indole group that lies adjacent to the gatekeeper residue (THR-
790).38 Hence, even when the threonine is substituted with the bulky methionine as a result 
of the T790M mutation the activity of osimertinib is retained.   
In November 2015 osimertinib was FDA approved for the treatment of metastatic NSCLC in 
patients with mutant T790M EGFR after failure of either the first or the second generation 
EGFR-TKIs.39 Several pre-clinical trials were conducted that demonstrated effective activity 
and safety of osimertinib both in vitro and in vivo and these findings led to the approval of 
osimertinib. 
During phase I studies in NSCLC patients with mutation positive EGFR, no dose limiting 
toxicities were observed. The most commonly observed toxicities were diarrhoea, nausea 
and rash.40 At high dose levels between 160 and 240 mg/d the observed toxicities became 
more severe and frequent; this was thought to be as a result of the inhibition of the wild type 
EGFR at such high doses.40 As a result, a recommended daily dose of 80 mg was adopted.40 
The observed response rate and progression free survival was superior for the EGFR 
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mutant positive patients as compared to the mutant negative patients. The response rate 
was 67% for mutant positive patients, and for mutant negative patients the response rate 
was as low as 21%.39,40 Furthermore, the progression free survival was longer for mutant 
positive patients (9.6 months) as compared to the mutation negative patients (2.8 months).40  
To assess the safety and efficacy of osimertinib, phase II studies were conducted using the 
recommended daily dose of 80 mg in NSCLC patients with mutant T790M EGFR.40 Results 
confirmed that osimertinib provided good clinical efficacy with a good toxicity profile.41 The 
observed overall response rate was 66% and the progression free survival was 11 months.41 
Osimertinib is currently undergoing phase III clinical trials. This particular study is 
investigating the efficacy of osimertinib as a first line treatment for NSCLC patients with 
either the primary mutations (exon 19 deletion and L858R point mutation) or the secondary 
acquired T790M mutation. The study also aims to investigate the efficacy of osimertinib as a 
second line treatment for NSCLC patients with specifically the acquired secondary T790M 
mutation.42  
Despite the good clinical efficacy demonstrated by osimertinib for the treatment of NSCLC 
patients with mutant positive EGFR, acquired resistance develops after an average of 8-10 
months of treatment, making the drug ineffective. Among a number of mutations that are 
thought to result in the observed resistance, the C797S mutation located within the EGFR 
tyrosine kinase domain was found to be the most prominent mechanism.39,40   
1.3.4.2. Mechanism of acquired resistance to third generation EGFR-TKIs 
As it has been previously noted that the formation of a covalent bond between third 
generation EGFR-TKIs and the Cys797 residue is required for growth inhibition of NSCLC 
cells with the T790M mutation, the mutation of this amino acid was considered as a feasible 
candidate for the observed resistance mutation.40 The C797S mutation was found to be the 
most common mechanism leading to the observed resistance of EGFR to third generation 
inhibitors.39,40 The C797S mutation is known to be a tertiary substitution mutation where the 
cysteine in the 797 position is substituted by a serine amino acid, resulting in an impaired 
target for the covalent bond formation with the third generation EGFR-TKIs, osimertinib to be 
specific.39 Hence it hinders the formation of a  covalent bond between the drug and the 
target. 
Studies have demonstrated various ways in which the C797S mutation in EGFR harbouring 
the T790M mutation could potentially be inhibited. Since first generation EGFR-TKIs don’t 
require the formation of a covalent bond with the Cys797 residue for effective inhibition 
activity, they could subsequently be used to inhibit EGFR in NSCLC patients that have 
acquired the C797S mutation.43 To validate this hypothesis, erlotinib was found to be 
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effective in inhibiting EGFR with the C797S mutation in vitro.43 These results opened new 
therapeutic strategies, demonstrating that for mutant T790M EGFR cells that have 
developed the C797S mutation upon treatment, combination or subsequent therapy of first 
and third generation EGFR-TKIs could be effectively explored.39 That is because neither the 
T790M nor the C797S mutation alone would be effective in mediating resistance to the 
combined therapy of EGFR-TKIs; i.e. osimertinib would inhibit the secondary T790M 
mutation while erlotinib inhibits the tertiary C797S substitution mutation.39,43 
Furthermore, studies have discovered an interesting effect of the configuration of the two 
mutations (the T790M and the C797S) in the tyrosine residue of EGFR to the combination 
therapy. Studies have shown that the allelic context in which the C797S mutations was 
developed may predict the efficacy of the EGFR-TKIs.39,43  When the two mutations are cis 
to each other, then the NSCLC cells become completely resistant to all three generations of 
EGFR-TKIs and even to combination therapy.39,43 However, when the mutations are trans to 
each other, then the combination therapy using first and third generation EGFR-TKIs 
becomes effective.39,43 These results demonstrated that whether the C797S is cis or trans to 
the T790M potentially has an impact on drug response, and that it has useful clinical 
implications which should be prioritised going forward.43  
The presence of the T790M mutation together with the C797S mutation was not the only 
biomarker that was observed during the study of NSCLC patients with T790M positive 
EGFR, who had developed resistance to the third generation EGFR-TKIs. Other subtypes 
included cells that had the T790M mutation without the C797S mutation and EGFR cells that 
were negative of both the T790M and C797S mutation.38,39 New therapeutic strategies had 
to be explored going forward. Since all  mutant selective EGFR-TKIs target the ATP binding 
site of EGFR, current research is exploring new therapeutic strategies by applying a different 
mechanism of action. One emerging strategy is the use of inhibitors targeting the allosteric 
sites in the tyrosine kinase domain of EGFR,46 another emerging strategy is the 
development of drugs that covalently and reversibly bind into the ATP binding pocket.45 
1.3.5. Recent developments: Overcoming the T790M and C797S drug 
resistance 
There is a great limitation observed with the currently existing EGFR-TKIs that are designed 
to target NSCLC patients that have acquired resistance. First generation EGFR-TKIs are 
effective towards the wild type EGFR and against EGFR that has somatic mutations (exon 
19 deletion and L858R point mutation); however patients develop resistance towards this 
drug after an average time of 14 months.23 The resistance was found to be due to the 
secondary T790M acquired mutation. Second generation drugs were then developed with 
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the aim of targeting the T790M mutation. Although these drugs were effective towards both 
the wild and mutant EGFR in vitro, they didn’t show any profound effectiveness towards the 
inhibition of the T790M mutation in vivo. Their limitation was found to be the narrow 
therapeutic window which precluded dosages that would be efficient for the inhibition of the 
T790M mutation.37,38 The next strategy applied was the development of third generation 
EGFR-TKIs which were still targeted towards the T790M mutation. Although these drugs are 
effective against the targeted mutation, resistance arises rapidly.39,40 The C797S mutation 
appears to be the most common mechanism of acquired resistance to third generation 
EGFR-TKIs.39,40  
This highlights the need for new therapeutic strategies that will overcome both the T790M 
and C797S mutation in NSCLC patients. The two classes of compounds to be discussed 
below are still in their developing stages.  
1.3.5.1. Fourth generation EGFR-TKIs 
There is an emerging interest in therapeutic strategies with a different mechanism of action 
as compared to the already existing ATP-competitive inhibitors. Recent investigations have 
discovered fourth generation inhibitors that could potentially overcome the drug resistant 
T790M and C797S mutations.39 Fourth generation EGFR-TKIs are allosteric inhibitors that 
bind to EGFR, but not in the ATP binding site (Figure 1.8).46 EA1001 (8, Figure 1.9) was the 
lead compound that was discovered to have good efficacy and selectivity against mutant 
EGFR; i.e. at a concentration of 1mM ATP the IC50 for the inhibition of L858R/T790M mutant 
EGFR was 0.024 μM as compared to  > 50 μM required for the wild type EGFR inhibition.46 
However, compound 8 didn’t show any exceptional inhibitory effect towards the individual 
L858R and T790M mutations.46 A structure based optimisation strategy was done and the 
most active compound was EA1045 (9, Figure 1.9). The compound was a result of replacing 
the unsubstituted benzene group in EA1001 with a 4-fluorophenol group. EA1045 was found 
to have profound potency and selectivity for the inhibition of L858R/T790M mutant EGFR.46 
In vitro studies also indicated that EA1045 is effective and selective for the T790M mutant 
EGFR that is in its inactive monomer state.46  
18 
 
   
Figure 1.8: Allosteric binding of fourth generation inhibitor EA1001 (8) to EGFR kinase domain away 
from ATP binding cleft.39 The yellow/green structure represents the EA1001 inhibitor and the 
grey/purple structure represents ATP still in its active site. 
 
 
Figure 1.9: Chemical structures of the fourth generation EGFR-TKIs. 
When EA1045 was used in mice containing the L858R/T790M/C797S mutant NSCLC 
tumour xenografts it wasn’t effective alone. However, in combination with cetuximab high 
tumour regression was observed39,46 thus indicating the importance of combination treatment 
as a potential key therapeutic strategy going forward. This study clearly revealed that 
EA1045 has the potential of overcoming the T790M and the C797S mutations, but only if 
EGFR dimerisation is inhibited.39 This explains why the combination of EA1045 and 
cetuximab was effective. No human clinical trials have been done as yet to validate the 
efficacy and safety of this compound in NSCLC patients as it is still in its developing stages. 
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Given the diversity of the resistance mechanisms observed with each generation of EGFR-
TKIs, combination therapy of EGFR-TKIs with other classes of inhibitors might be one of the 
most promising therapeutic strategies to be applied for the treatment of NSCLC patients. 
1.3.5.2. Covalent reversible EGFR-TKIs 
Although there has been great success observed with the covalent inhibitors, the 
progressive emergence of drug resistant mutations in the active site demonstrated the need 
for continuous development of new generations of EGFR-TKIs. Some recent developments 
are focused on an alternative innovative class of compounds: the covalent reversible 
inhibitors. That is, this class of compounds has a covalent yet reversible warhead instead of 
the covalent irreversible warhead observed with the second, third and fourth generation 
inhibitors.45 Covalent reversible EGFR-TKIs are theoretically devoid of the drawbacks 
observed with the conventional covalent irreversible inhibitors, yet they still have the 
potential to combine their positive effects.45,52 Investigations have indicated that irreversible 
binding is not required for effective inhibition of the mutant EGFR, a reversible inhibitor with 
sufficient affinity to outcompete ATP should work as well.34  
One relevant determinant of any inhibitors’ efficacy is its residence time towards its target 
active site.54 For the development of inhibitors that outcompete the natural ATP in its active 
site it became of importance to develop inhibitors with optimised prolonged drug-target 
residence time and covalent binding nature afforded this characteristic.52 The reversible 
nature was then introduced to eliminate toxicity and resistance issues often observed with 
irreversible covalent binding.52,55 Taunton and co-workers showed that a rapid reversible 
bond can be formed between the target protein and an inhibitor containing electron deficient 
olefins (Scheme 1).51,52,58   
 
 
Scheme 1: Representation of the reversible covalent Michael addition of thiols to electron deficient 
Michael acceptors. Where, R = aromatic ring and R’ = NH or O- alkyl.58 
Based on this strategy several other studies have focused on designing compounds with the 
α-cyano-α,β-unsaturated carbonyl warhead to explore the concept of covalent reversible 
inhibition of drug resistant EGFR.45,52 Although these compounds are still used as tool 
compounds, here we will briefly discuss the successes that have been achieved thus far. 
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A study by Basu and co-workers reported a structure based design of covalent reversible 
EGFR inhibitors,45 wherein they designed and synthesised a library of compounds based on 
the WZ4002 (7) scaffold. To afford the covalent reversible characteristic, the Michael 
acceptor of compound 7 was chemically tuned by the introduction of electron withdrawing 
groups at R1 resulting in an electron deficient olefin (10, Figure 1.10). The synthesised 
compounds were then biochemically evaluated. 
 
 
Figure 1.10: Chemical structure of the third generation EGFR-TKI WZ4002 (7), the design of covalent 
reversible inhibitors (10 and 11) and the control compound used to investigate the effect of the 
electron withdrawing group (12). Where, R1 = electron withdrawing group and R2 = aliphatic or aryl 
group. 
A series of these compounds were found to be highly selective and displayed a strong 
inhibitory effect towards the mutant EGFR compared to the wild type EGFR in vivo.45 Cyano 
and fluoro electron withdrawing groups were explored, and it was observed that the cyano 
containing compounds were generally more potent. To evaluate whether the electron 
withdrawing cyano group had any effect on the inhibitory activity of the compounds, 
compounds 11 and 12 were directly compared (Figure 1.10). Compound 11 was ten times 
more potent than compound 12,45 which indicated that the electron withdrawing group does 
indeed increase the inhibitory effect of this drug. This study indicated that α-cyano-α,β-
unsaturated compounds are a promising class of compounds for mutant EGFR inhibition, 
however, further investigations are still required for their development. 
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1.4. An alternative approach to covalent reversible EGFR-TKIs 
The search for covalent reversible inhibitors is not limited to compounds containing the 
cyanoacrylate functional group, several other functional groups can be chemically tuned 
such that they become covalent reversible warheads. One important aspect is for the 
reactive warhead to produce a labile cross-linked product upon attack by the serine or 
cysteine of the biological target.51 Any functional group that has this characteristic serves as 
a potential moiety for the development of covalent reversible inhibitors. Reversibly reactive 
moieties include aldehydes, ketones, nitriles and boronic acids.51 Boronic acids and 
aldehydes have been widely used as protease inhibitors. 
Of interest to us are ketones or rather α-keto carbonyl/amide compounds. Activated ketones 
such as α-keto esters, α-keto acids and α-keto amides have been reported to reversibly 
inhibit cysteine proteases.57 These functional groups form a short-lived reversible covalent 
bond with the cysteine thiol (Scheme 2).57 This results in a reversible equilibrium between 
the inhibitor and the formed hemithioketal. The inhibition effect of these α-keto carbonyl 
compounds has, however, not been investigated in kinase enzymes.  
 
 
Scheme 2: Representation of the reversible inhibition of a protease enzyme by a compound 
containing the ketoamide warhead. 
EGFR-TKIs containing the α-keto carbonyl warhead have, to date, not been studied in any 
research group. In this work, we set out to explore the covalent reversible inhibition of EGFR 
using α-ketoamide containing compounds. Ketoamides have been used to make protease 
inhibitors with some success. This current approach could be valuable since the cysteine 
nucleophile will still be used, just in a different enzyme. It is thus an intuitive hypothesis that 
the reversible nature of the bond formed between the two substrates will still be retained 
even in our systems. Such an approach might lead to compounds which can form reversible 
covalent bonds with the cysteine (Cys797) residue of EGFR and hopefully selectively inhibit 
the mutant type EGFR while sparing the wild type EGFR in order to avoid any undesired 
side effects.  
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1.5. Aims of this project 
Given the potential that the activated ketone warhead approach could offer in drug 
discovery, it is therefore essential to study the effect of this warhead in EGFR inhibition. This 
project is based on literature results that have demonstrated that effective inhibition of EGFR 
is not restricted to irreversible binding. A reversible inhibitor that binds with sufficient affinity 
to surpass ATP should work as effectively. This current work will explore the concept of 
covalent reversible inhibitors for the inhibition of EGFR in NSCLC treatment, by specifically 
applying the α-ketoamide warhead. The α-ketoamide warhead may allow for reversible 
covalent bond formation with EGFR, through the formation of a hemithioketal similar to the 
one represented in Scheme 2. In this study we aim to design, synthesise and test the 
synthesised pyrimidine ketoamides for biological activity against EGFR.  
Considering the progressive drug resistance and observed toxicities with current EGFR-
TKIs, our objective will be to synthesise highly competitive or effective EGFR-TKIs that will 
not introduce any severe side effects. Since their binding will be reversible, these inhibitors 
will compete with ATP at the receptor catalytic domain to avoid autophosphorylation and the 
downstream intracellular signalling from occurring.  
1.5.1. Design of target compounds 
Computational molecular modelling was previously done in our laboratory by Dr Allan Prior 
to determine the optimal drug scaffold, predict preferred binding conformations and also 
calculate the binding energy of the designed molecules. A library of pyrimidine ketoamides 
was designed and modelled using Accelrys (Biovia) Discovery Studio 4.0. The pyrimidine 
core was designed to mimic the adenine base of ATP and an appropriate side-chain was 
added that would position the activated ketone in such a way that it could form covalent 
reversible bonds with the target cysteine thiol. Modelling of these pyrimidine ketoamides in 
the T790M mutated EGFR (PDB code: 4I24) showed that they preferred to dock with the N-
aryl group pointing towards a hydrophobic pocket at the back of the active site near MET790 
(Figure 1.11A). The pyrimidyl core bound to the hinge region and formed a hydrogen bond to 
MET793 (NH) via the pyrimidyl nitrogen with an average distance of 1.85 Å. Predominantly, 
the ethylene glycol linker was positioned near the edge of the pocket which placed the 
electrophilic ketoamide carbonyl close to thiol of CYS797 with a distance of 3.63 Å. This 
suggested that covalent bond formation between the bound ketoamide inhibitor and the thiol 
(CYS797) may be possible. Based on this model, a series of pyrimidine ketoamides bearing 
different aniline substrates was proposed for synthesis in this project (Figure 1.11B).     
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R = 3-bromo  
    = H 
    = 3-chloro-4-fluoro 
    = 3-ethynyl  
    = 3,5-dimethoxy 
    = 3,4-difluoro 
    = 2-chloro-4-((3-fluorobenzyl)oxy) 
    = 3-chloro-4-((3-fluorobenzyl)oxy) 
 
Figure 1.11: A: Highest scored docked pose of the pyrimidine ketoamides with T790M mutated EGFR 
(PDB: 4I24).  B. Chemical structure of the proposed anilino-pyrimidine ketoamide molecules. 
1.5.2. Chemistry 
Scheme 3 outlines the retrosynthetic strategy towards desired pyrimidine ketoamide 
molecules. We plan to synthesise the pyrimidine ketoamides 13a-h by the oxidation of α-
hydroxy amide intermediates 14a-h, which can be accessed using isocyanide chemistry with 
isopropyl isocyanide and the aldehydes 15a-h. Compounds 15a-h can be accessed from the 
oxidation of compounds 16a-h using IBX. We plan to synthesize 16a-h from the 
monoprotected diethylene glycol 17, 4,6-dichloropyrimidine 18 and various anilines 19a-h. 
Scheme 4 details the proposed step for the monoprotection of diethylene glycol to yield the 
desired precursor 17.  
Once this methodology has been successfully applied for the synthesis of pyrimidine 
ketoamide molecules, they will be screened for anti-cancer activities by Dr. Leonie Harmse, 
Department of Pharmacy and Pharmacology, University of the Witwatersrand. We also wish 
B      A 
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to investigate a different activated ketone group that has the potential of forming a reversible 
covalent bond with the cysteine thiol. The anilino-pyrimidine scaffold will be retained, only 
changing the ketoamide warhead to a ketoester to afford compounds of the general 
chemical structure shown in Figure 1.12. 
 
 
Scheme 3: Retrosynthetic strategy towards ketoamides. 
 
Scheme 4: Reagents and conditions: p-TSA, 0 – 25°C, 24 h 
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Figure 1.12: Chemical structure of the proposed anilino-pyrimidine ketoester molecules. 
In a similar manner to ketoamides, we plan to access the ketoester 20 by the oxidation of α-
hydroxy ester 21 (Scheme 5). Compound 21 can be accessed by sequential hydrolysis and 
esterification of cyanohydrin 22, which we plan to synthesise by reaction of potassium 
cyanide (KCN) and aldehyde 15. 
 
 
 Scheme 5: Retrosynthetic strategy towards ketoesters. 
Through this work, we hope to discover new α-ketoamide EGFR inhibitors with promising 
anti-cancer activities. We also hope that this project will identify the best anilino-pyrimidine 
scaffolds that can be used for T790M EGFR inhibition, and hence influence future 
developments in the search for covalent reversible EGFR-TKIs.  
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CHAPTER 2: RESULTS AND DISCUSSION 
 
2.1. Synthesis of pyrimidine ketoamides as EGFR inhibitors 
As per the aims discussed in Chapter 1, this project focused on the synthesis of anilino-
pyrimidine molecules as potential EGFR-TKIs for cancer treatment. Scheme 3 outlined the 
retrosynthetic strategy towards the desired ketoamide molecules. Scheme 6 below outlines 
an overview of the proposed synthetic route towards the target compounds 13a-h. 
 
Scheme 6: Overview of the proposed synthetic route towards the pyrimidine ketoamides 13a-h 
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Steps (i) and (ii) would involve two nucleophilic displacements of the chloro groups of 
compound 18: one by the aniline derivatives 19a-h and one by the monoprotected 
diethylene glycol chain 17. In step (iii) compound 16 would then be oxidised to give the 
aldehyde 15. Using isocyanide chemistry compound 15 would undergo functional group 
interconversion to give compound 14 in step (iv), which would be oxidised to give the target 
compound 13 in the final step.  
The synthesis began with the preparation of the two general intermediates; 2-[2-(tetrahydro-
2H-pyran-2-yloxy)ethoxy]ethanol 17 and 4,6-dichloropyrimidine 18.  
The atom numbering on compounds does not follow the official IUPAC rules. The atoms 
were numbered to simplify the discussion of assignments. The m/z values reported in the 
following sections are for compounds containing the 79Br or 35Cl isotopes. 
2.1.1. The synthesis of 2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethanol 1 
Compound 17 was synthesised from the commercially available diethylene glycol 23 
(Scheme 7). Monoprotection of one hydroxyl group on diethylene glycol 23 was performed 
using 3,4-dihydro-2H-pyran 24 in the presence of p-toluenesulfonic acid (p-TSA). The 
desired compound 17 was obtained as a clear oil in 69% yield, which corresponded to the 
results obtained by Tian et al.59 
 
Scheme 7: Reagents and conditions: p-TSA, 0 – 25°C, 24 h, 69% 
Upon 1H NMR spectroscopic analysis of compound 17, a triplet characteristic of H-5 was 
observed at δ 4.64. Another characteristic peak was observed as a multiplet between δ 1.91 
– 1.48 integrating for 6 protons; which was assigned to be overlapping signals for H-6, H-7 
and H-8. Furthermore, five other multiplets were observed between δ 3.92 – 3.41, which in 
total integrated for 11 protons: corresponding to those protons attached to carbon atoms 
bearing oxygen (H-1, H-2, H-3, H-4, H-9) and OH. The 13C NMR spectrum showed a total of 
nine signals which indicated that the molecule was no longer symmetrical and a new 
functional group had been introduced. The signal observed at δ 99.1 was characteristic of C-
5 and that indeed confirmed that the diethylene glycol chain had been monoprotected.  
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2.1.2. The synthesis of 4,6-dichloropyrimidine 18 
For many years the preparation of 4,6-dichloropyrimidines from their corresponding 
dihydroxypyrimidines has been carried out using excess phosphoryl chloride (POCl3)60 and 
we followed the same procedure for this synthesis. To synthesise compound 18 
commercially available 4,6-dihydroxypyrimidine 25 was refluxed with POCl3 , resulting in the 
chlorinated compound 18 in 59% yield (Scheme 8). The obtained 59% yield was in 
agreement with the 58% yield obtained by McCluskey et al. when chlorinating structurally 
similar compounds.60 Only two aromatic  singlets integrating for one proton each were 
observed in the 1H NMR spectrum of 18, one at δ 8.97 assigned to H-1’ and the other one at 
δ 8.11 assigned to H-3’. The absence of peaks corresponding to the hydroxyl groups was a 
clear indication that the reaction had taken place. Further confirmation was obtained from IR 
spectral analysis, no OH stretching peaks were observed between 3200 – 3600 cm-1. From 
the 13C NMR spectrum three signals were observed, one at δ 162.1 assigned to C-4’ and C-
2’ and the others at δ 158.8 and 121.9 assigned to C-1’ and C-3’, respectively.  
 
Scheme 8: Reagents and conditions: POCl3, reflux, 3 h, 59% 
2.1.3. The synthesis of 2-{2-[4-(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy} 
ethanol 16a and analogues 
With the two general intermediates 17 and 18 in hand, the amino pyrimidine ethanol 
compounds 16 could be accessed in one of two approaches (Scheme 9). In the first 
approach (a) the first chloro group of compound 18 is substituted by an aniline derivative 19 
and the second chloro group is subsequently displaced by the monoprotected diethylene 
glycol chain 17.   In the second approach (b) the sequence of nucleophilic displacements is 
reversed.  
The aniline derivates were commercially available. Three of the anilines 19c-d, h have been 
used in FDA approved EGFR-TKIs, hence we chose them. The other aniline derivatives 
were chosen to investigate the effect of electron-withdrawing substituents against electron-
donating substituents. 
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Scheme 9: Two possible approaches, a and b, for the synthesis of compounds 16 
2.1.3.1. The first approach (a) towards the synthesis of 2-{2-[4-(3-bromophenylamino) 
pyrimidin-6-yloxy]ethoxy}ethanol 16a  
The synthesis began with the preparation of intermediate 26a from the already synthesised 
compound 18. The 3-bromoaniline 19a group was installed by sequential addition of ethanol, 
3-bromoaniline and triethylamine to a round bottomed flask containing 2,4-dichloropyrimidine 
18 (Scheme 10(i)). The reaction was refluxed at 80oC and monitored by thin layer 
chromatography (TLC). This step afforded the desired product 26a (as confirmed by 1H NMR 
spectroscopy and MS) in 16% yield. 
In the 1H NMR spectrum of compound 26a five additional signals were observed accounting 
for the installed anilino moiety. The presence of a singlet integrating for one proton at δ 
10.03 was characteristic of the amino group. Another characteristic feature was the upfield 
shift of the H-3’ proton from δ 8.11 to δ 6.84. This indicated that chlorine had been 
substituted with the amino group which donates electron density to the ortho position (H-3’) 
through resonance. Aromatic signals characteristic of the bromoaniline group were observed 
between δ 8.06 and 7.24. Further confirmation was obtained from the 13C NMR spectrum 
where the C-2’ and C-4’ signals were no longer observed in the same environment indicating 
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that a new moiety had been installed resulting in the loss of symmetry of the pyrimidine 
scaffold. The signal at δ 160.9 was assigned to C-2’ and that at δ 158.4 to C-4’, the slight 
upfield shift observed with the C-2’ signal was characteristic of the electron donating effect of 
the amino group. The upfield shift in the δ value of C-3’ from δ 122.0 to δ 105.7 also 
confirmed that the aniline group had been installed. Six more signals were observed at δ 
140.7, 130.7, 125.5, 122.2, 121.6 and 118.8 which were characteristic of the bromoaniline 
carbon atoms.   
 
Scheme 10: Reagents and conditions: i. 3-BrPhNH2 19a, Et3N, EtOH, reflux, 18 h, 55%; ii. 17, NaH, 
DMF, 150°C, 3.9% or NaH, DMSO, 150-160°C,16% ; iii. 4M HCl, r.t., overnight, 57% 
Literature states that 4,6-dichloropyrimidines should undergo aminolysis quite easily.62 The 
16% isolated yield for compound 26a was undesirable and we believed that the product was 
lost during the reaction workup. An alternative workup procedure had to be investigated to 
optimize both the yield and purity of the desired product.  Thus the reaction was repeated as 
before but once all the starting material had reacted based on TLC analysis, a test workup 
procedure was performed on a 10 mL portion of the 100 mL reaction mixture. The 10 mL 
reaction mixture was first dissolved in ethyl acetate and consecutively washed with water, 
saturated ammonium chloride and finally saturated brine. This gave a yellow solid of mass 
913 mg which, according to 1H NMR spectroscopy, was a mixture of the desired product 26a 
and both of the starting materials, 18 and 3-bromoaniline 19a. The rest of the reaction, 90 
mL, was refluxed for a further 48 h. After that period, starting material 18 had completely 
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reacted; however, a significant amount of 3-bromoaniline 19a was still in the mixture (as 
confirmed by 1H NMR spectroscopy). It was decided to add more starting material 18 to the 
reaction in proportion to the excess 3-bromoaniline that remained in the reaction. After 
refluxing for a further 18 h the reaction went to completion (as confirmed by 1H NMR 
spectroscopy).  The crude reaction mixture was purified by liquid-liquid extraction. Similar to 
the previous extraction, the reaction mixture was dissolved in EtOAc and consecutively 
washed once with water, twice with saturated ammonium chloride and finally once with 
saturated brine. The desired product 26a was obtained as an orange solid in 55% yield. 
Although the isolated yield had significantly improved, the yield was still not optimal 
considering that this step was towards the beginning of our synthesis. The reaction was 
repeated, but this time compound 18 was used in excess. The workup was also further 
simplified: during the workup diethyl ether was added to the reaction mixture to precipitate 
the triethylammonium chloride salt; the filtrate was then washed once with water and the 
collected organic layer was concentrated in vacuo to give a yellow solid which was washed 
with water (via sonication) to afford desired product 26a (as confirmed by 1H NMR 
spectroscopy and MS) in a much improved yield of 86%.  
The next step was then the displacement of the second chlorine group in 26a by 2-[2-
(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethanol 17 (Scheme 10(ii). This reaction was carried 
out by reacting a solution of 26a in DMF with that of compound 17 and sodium hydride in 
DMF and heating at 150°C. Previous attempts to do this reaction at lower temperatures (80-
110°C) had resulted in no reaction occurring, highlighting the need for much higher reaction 
temperatures for this nucleophilic substitution reaction. This procedure, however, produced 
the desired product as a minor product and a major undesired product as confirmed by NMR 
spectroscopy and MS. Under our reaction conditions, at high temperatures such as 150°C, it 
appeared that hydride (H-) attacks the electrophilic carbon atom of DMF resulting in the 
formation of a N,N-dimethylamide anion (–N(Me)2) 28 (Scheme 11). The two anions, 17 and 
28 then compete for chlorine substitution on 26a, and in this case the major product was a 
result of 28 acting as a nucleophile instead of anion 17 (as confirmed by 1H NMR 
spectroscopy and MS) (Scheme 11). From the 1H NMR spectrum of 29a it was evident that 
17 had been installed, additional peaks were now observed in the aliphatic region. One 
significant signal integrating for one proton was observed at δ 4.63 which was characteristic 
of H-5. In addition to the expected aromatic signals, several multiplets were observed 
between δ 4.51 to 3.41 which in total integrated for 10 protons and they were assigned to    
H-1, H-2, H-3, H-4 and H-9. From the 1H NMR spectrum of 30a one significant singlet 
integrating for six protons was observed at δ 3.05 and that was assigned to H-11’ (Scheme 
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11). The separation of the two compounds by silica gel column chromatography was difficult 
as they both had very similar Rf values.  
 
Scheme 11: Under our reaction conditions, at high temperatures (150°C) in the presence of hydride, 
it appeared that DMF decomposes into N,N-dimethylamide anion. 
To solve the problem at hand the reaction was repeated, but this time using dimethyl 
sulfoxide (DMSO) as a solvent which would not be prone to decomposition by hydride. The 
reaction then produced an oil which contained both the starting material 26a and the desired 
product 29a (as confirmed by 1H NMR spectroscopy and MS).The oil was then purified over 
a silica gel column to give 29a in a very poor 16% yield and 4% of the starting material 26a 
was recovered. The presence of the starting material was a result of the reaction stopping 
before 100% conversion of the starting material, but prolonged reaction time was ineffective 
in resolving this matter. To account for the very low yield, the probability is that the product 
decomposes during the reaction; however, no detailed analysis was carried out. Due to the 
observed yields being very low a second approach (b) was explored as an alternative 
method where the diethylene glycol chain 17 was attached prior to the amination reaction 
(Scheme 9). 
2.1.3.2. The second approach (b) towards the synthesis of 2-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}ethanol 16a  
This second approach began with the synthesis of intermediate 31 (Scheme 12). 
Theoretically, the nucleophilic substitution of 4,6-dichloropyrimidine by an alkoxide ion 
should not be difficult. The pyrimidine ring is activated towards nucleophilic displacement by 
the electron withdrawing effect of the other chlorine atom.62 As expected, no difficulties were 
observed with this reaction even though the isolated yield was moderate. 
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Scheme 12: Reagents and conditions: NaH, THF, 0 – 25°C, 48 h, 54%  
The monoprotected diethylene glycol 17 was deprotonated using NaH in THF and reacted 
with 4,6-dichloropyrimidine 18 to afford the desired product 31. The reaction was performed 
by stirring under nitrogen atmosphere at room temperature for 48 h. Any observed impurities 
(from TLC analysis) were removed by silica gel column chromatography to give compound 
31 as a colourless oil in 54% yield.  
Nine signals were observed from the 1H NMR spectrum of 31. Amongst the nine signals two 
singlets in the aromatic region were observed at δ 8.56 and δ 6.83, each integrating for one 
proton which were assigned to H-1’ and H-3’ respectively. The aliphatic region contained a 
triplet at δ 4.63 integrating for one proton, and a multiplet at δ 4.57 integrating for two 
protons, characteristic of H-5 and H-1 respectively. Furthermore, the presence of a multiplet 
at δ 3.76 – 3.69 integrating for two protons and a multiplet at δ 1.88 – 1.47 integrating for six 
protons confirmed that compound 31 was successfully synthesized. The first multiplet was 
characteristic of H-3 and the second multiplet was characteristic of H-6, H-7 and H-8. In the 
13C NMR spectrum, the presence of two quaternary carbon atoms attested to the fact that 
the substitution of one chlorine atom had indeed occurred as C-2’ and C-4’ were no longer in 
the same environment. In the 13C NMR spectrum of the starting material 18, C-2’ and C-4’ 
both appeared as one signal at δ 162.1; while for compound 31  we observed C-2’ at δ 170.1 
and C-4’ at δ 160.6. Conclusive evidence was obtained from the high resolution mass 
spectrum (HRMS) of 31. A molecular ion peak was observed at m/z 303.1106 which was in 
agreement with the calculated [M+H]+ for C13H20ClN2O4 of 303.1103. 
With compound 31 in hand we were now in a position to do the amination reaction to afford 
the anilino-pyrimidine alcohol compounds. Our first attempt was to try this reaction under 
basic conditions. Unfortunately, when 31 was coupled with 3-bromoaniline 19a in the 
presence of sodium hydride (NaH) in tetrahydrofuran (THF) no reaction was observed 
(Scheme 13). The reaction was initially performed at room temperature overnight and upon 
TLC analysis, a spot in correspondence with starting material 19a was observed Rf = 0.78 
(50% EtOAc:Hex) and a spot corresponding to 31 with Rf = 0.55 (50% EtOAc:Hex) was 
observed. The temperature was raised to 70°C, and upon TLC analysis both starting 
materials had been consumed. Unfortunately, the 1H NMR spectrum of the crude material 
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obtained from the reaction mixture did not indicate the presence of either the starting 
materials or the desired product. We then changed the solvent to DMSO and the reaction 
was heated at 150°C overnight, but no reaction occurred as confirmed by TLC analysis.  
  
Scheme 13: Reagents and conditions: NaH, THF, r.t. – 70°C, overnight, no reaction 
A strong base, potassium bis(trimethylsilyl)amide (KHMDS) was then used for the base 
catalysed amination reaction (Scheme 14). Initially 2-propanol was used as a solvent for this 
reaction and after stirring overnight at room temperature only the starting materials were 
present, as confirmed by TLC. The reaction mixture was then refluxed overnight and a new 
product had formed as seen by TLC. The observed new spot was less polar than both 
starting materials. This contradicted what was expected as the desired product was 
expected to be more polar than the starting materials. The mixture was purified using silica 
gel column chromatography and the new spot was submitted for characterization by 1H NMR 
spectroscopy. 1H NMR spectroscopic analysis showed the presence of a doublet integrating 
for six protons at δ 1.36, a septet at δ 5.39 integrating for one proton, and two singlets at δ 
6.73 and 8.56. This suggested that KHMDS had deprotonated the hydroxyl group of 2-
propanol instead of the amine of 19a. 2-Propanol then acted as both a solvent and a 
nucleophile, substituting the diethylene glycol chain to give the undesired product 32. The 
doublet and septet could then be assigned to H-2 and H-1, respectively. 
                   
 
Scheme 14: Reagents and conditions: KHMDS, 2-propanol, 80°C.  
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Further attempts to carry out this transformation then involved varying the solvent and 
observing the results. The second solvent tried was DMF (Scheme 15); however, this 
solvent also didn’t yield the desired product. Although DMF had proved to act as a 
nucleophile in our previous reactions (Scheme 11), that was only when the reaction 
temperature was raised to 120°C. At temperatures lower than 120°C DMF had not been 
observed to be a competing nucleophile. However, for the present reaction at 80°C instead 
of the nitrogen on 19b acting as a nucleophile, (-N(Me)2) 28 acted as a nucleophile 
substituting the chlorine atom on compound 31 to give the undesired product 33. As 
expected, the 1H NMR spectrum of 33 was very similar to that of starting material 31 except 
that we now observed a prominent singlet at δ 3.06 integrating for six protons. The singlet 
was assigned to H-5’ and that confirmed that 31 had undergone a nucleophilic substitution 
by 28.  
 
Scheme 15: Reagents and conditions: KHMDS, DMF, 80°C. 
The next attempt was made using DMSO as a solvent. Little success was achieved for this 
reaction as the reaction rate was very slow. Prolonged reaction times or increasing the 
number mole equivalents of KHMDS proved ineffective; a small fraction of the starting 
material was converted into the product and the reaction would not proceed any further. In 
most cases more than 95% of the starting material was recovered. 
After this failed attempt we then decided to try a palladium-catalysed cross-coupling 
reaction, employing tris-dibenzylideneacetone di-palladium [Pd2(dba)3] as a pre-catalyst and 
(rac)-BINAP as a supporting ligand (Scheme 16).  
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Scheme 16: Reagents and conditions: 2-4 mol% Pd2(dba)3, 6-12 mol% (rac)-BINAP, K2CO3, DMSO, 
80°C, 24-96 h.  
The choice of both the pre-catalyst and the supporting ligand was based on the findings of 
Changunda et al. that using Pd2(dba)3 as a palladium source and (rac)-BINAP as a 
supporting ligand was generally successful for C-N, C-O and C-S cross-coupling reactions.61 
In order to carry out the reaction, the catalyst was prepared in a round bottomed flask by 
adding Pd2(dba)3 and (rac)-BINAP in DMSO and stirred at 80°C for ten minutes under 
nitrogen purge. Compounds 31, 19a and K2CO3 were then consecutively added and the 
reaction was stirred at 80°C overnight. This afforded the desired product 29a in 20% yield. 
The reaction was repeated and the isolated yield slightly increased to 22%. One of the 
problems with using bromoaniline 19a is that it could participate in the cross-coupling 
reaction to give the homo-coupled product. Confirmation of the synthesis of compound 29a 
was obtained from 1H NMR spectroscopic analysis. The 1H NMR spectra of compounds 29a 
and 31 were very similar in the aliphatic region, however, the presence of two additional 
signals in the aromatic region confirmed that the amination reaction had occurred. Two 
singlets each integrating for one proton were observed at δ 8.35 and δ 6.16 and were 
assigned to H-1’ and H-3’, respectively. Additionally, a singlet integrating for one proton was 
observed at δ 7.51 and it could be assigned to H-6’. A multiplet integrating for three protons 
was also observed at δ 7.23 – 7.21 and it was assigned to H-8’, H-9’ and H-10’. To avoid the 
homo-coupling possibility we performed the reaction using aniline 19b, the desired product 
was afforded in 25% yield. The isolated yield of 25% was undesirable. In all cases starting 
materials 31 and 19 were recovered.  Other unidentified side products were also recovered. 
Analysis of the 1H NMR spectrum of the side products did not give a clear indication of what 
they were. Prolonged reaction times and the scaling up of the catalyst loading proved 
ineffective for yield optimisation. To improve the yield of the metal-catalysed amination for 
our substrate various other factors like the choice of our supporting ligand and an alternative 
mediating metal would have to be investigated. However, we decided to pursue alternative 
reactions. 
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One other attempt investigated for this transformation was an acid catalysed amination 
(Scheme 17). It was observed that the acid played two roles: catalysing the amination 
reaction and deprotection of 31. The deprotection of THP-protected alcohols under acidic 
conditions is a well-known reaction, but what was quite puzzling was the exact mechanism 
through which the acid catalysed the cross-coupling reaction. We imagined that the acid 
protonated the nitrogen atoms of compound 31 making the ring more electron deficient, thus 
activating it for nucleophilic substitution. This approach seemed to offer an advantage as two 
steps could be done as one. However, our initial results proved otherwise, with a lot of side 
products being formed which resulted in very low yields of the desired product 16a. Upon 
TLC analysis, roughly six spots were observed. The crude material was purified by silica gel 
column chromatography and all the products that were collected in reasonable quantities 
were submitted for NMR spectroscopic characterisation, but only the desired product could 
be identified.   
 
Scheme 17: Reagents and conditions: conc. HCl, 2-propanol, reflux, 24 h, 19% 
The 1H NMR spectrum of the product with Rf = 0.48 (94% DCM:MeOH) was confirmed to be 
the desired product. The 1H NMR spectrum had seven signals in the aromatic region; three 
singlets were observed at δ 9.58, δ 8.42 and δ 6.10, each integrating for one proton and 
were assigned to NH, H-1’ and H-3’ respectively. The other four signals observed in the 
aromatic region were due to the 3-bromoaniline: two triplets at δ 8.02 and δ 7.26 each 
integrating for one proton were assigned to H-6’ and H-9’, and the two doublet of doublet of 
doublets observed at δ 7.50 and δ 7.16 which also integrated for one proton each were 
assigned to H-8’ and H-10’, respectively. The absence of the multiplet at δ 1.88 – 1.47 
characteristic of H-6, H-7 and H-8 was enough proof that the deprotection had indeed taken 
place. Further confirmation that the amination reaction had occurred was obtained from 13C 
NMR spectroscopy: four quaternary carbon signals were observed which indeed align with 
the desired compound 16a. The IR spectrum of 16a had a broad signal at 3378 cm-1, which 
is characteristic of the OH group. The high resolution mass spectrum showed a molecular 
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ion peak at m/z 354.0448, consistent with the [M+H]+ for C14H17BrN3O3 of 354.0440, further 
confirming the formation of product 16a. Although the desired product 16a had been 
successfully synthesised, the 19% isolated yield was undesirable and further investigations 
had to be carried out for improvement. To try and improve the yield the deprotection of 31 
and the amination reaction were done as two separate steps.  
 
The deprotection was carried out in the presence of hydrochloric acid catalyst in 2-propanol 
at room temperature to afford compound 34 as a pale yellow oil in 63% yield (Scheme 18).  
 
Scheme 18: Reagents and conditions: conc. HCl, 2-propanol, r.t., overnight, 63%  
As expected the 1H NMR spectra of starting material 31 and product 34 were very similar; 
the absence of the triplet at δ 4.63 and the multiplet at δ1.88 – 1.47 in the spectrum of 34 
confirmed that the deprotection had indeed taken place as these signals are characteristic of 
the protecting group. A new OH stretch was observed in the IR spectrum of 34 at 3406 cm-1, 
which was further confirmation that the deprotection had occurred. Further confirmation was 
obtained from the HRMS spectrum of 34, a molecular ion peak at m/z 219.0531 was 
observed which was in good agreement with the calculated [M+H]+ for C8H12ClN2O3 of 
219.0529.  
The amination proceeded in the presence of HCl and afforded the desired compound 16a in 
41% yield as a pale yellow solid, as confirmed by NMR spectroscopic analysis (Scheme 19). 
The reaction failed to go to completion, as confirmed by TLC, but longer reaction times and 
addition of more of the acid catalyst seemed to be ineffective in improving the conversion. 
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Scheme 19: Reagents and conditions: conc. HCl, 2-propanol, reflux, 48 h, 41%  
A comparison of the yields obtained for the various attempts (Scheme 10 – 19) to perform 
the amination reaction indicated that the acid catalysed amination where we first deprotected 
the alcohol and then did the amination reaction gave the best yield. No further reaction 
conditions were investigated for the reaction. 
Seven other analogues 16b-h were then prepared through the acid catalysed amination of 
34 and they all gave moderate yields of the desired compounds (Scheme 20). As expected, 
the 1H and 13C NMR spectra of the products were similar, with small changes arising 
depending on the aniline used for the amination reaction. Key signals of the compounds are 
described in Tables 1 and 2 below. 
 
16b:  R = H, 73% 
16c:      = 3-chloro-4-fluoro, 62% 
16d:      = 3-ethynyl, 29% 
16e:      = 3,5-dimethoxy, 54% 
16f:       = 3,4-difluoro, 52% 
16g:      = 2-chloro-4-((3-fluorobenzyl)oxy), 13% 
16h:      = 3-chloro-4-((3-fluorobenzyl)oxy), 9% 
Scheme 20: Reagents and conditions: conc. HCl, 2-propanol, reflux, 48 h 
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The isolated yields were relatively good for all of the substituted anilines, with the exception 
of 16g & h. This was hypothesised to be an effect of steric hindrance, as both the anilines 
19g & h are sterically more hindered than the other derivatives. 
Table 1: Key signals in the 1H NMR spectra of the anilino-pyrimidine alcohols 16a-h 
Compound NH (ppm) H-1’ (ppm) Aniline protons (ppm) H-3’ (ppm) H-3 and H-4 
(ppm) 
16a 9.58 (s) 8.42 (s) 8.02 (t, H-6’), 7.50 
(ddd, H-8’), 7.26 (t, H-
9’), 7.16 (ddd, H-10’) 
6.10 (s) 3.55 – 3.44 
(m) 
16b 9.40 (s) 8.35 (s) 7.57 (d, H-6’ and H-
10’), 7.31 (t, H-7’ and 
H-9’), 7.01 (t, H-8’) 
6.08 (s) 3.56 – 3.44 
(m) 
16c 9.91 (s) 8.43 (s) 8.01 (dd, H-6’), 7.50 
(ddd, H-10’), 7.36 (t, H-
9’) 
6.16 (s) 3.57 – 3.44 
(m) 
16d 9.95 (s) 8.44 (s) 7.87 – 7.83 (m, H-6’), 
7.63 – 7.56 (m, H-10’), 
7.33 (t, H-9’), 7.16 – 
7.10 (m, H-8’) 
6.20 (s) 3.54 – 3.44 
(m) 
16e 9.36 (s) 8.37 (s) 6.84 (d, H-6’ and H-
10’), 6.19 (t, H-8’) 
6.09 (s) 3.54 – 3.46 
(m) 
16f 9.68 (s) 8.38 (s) 7.85 (ddd, H-6’), 7.39 – 
7.30 (m, H-9’), 7.29 – 
7.22 (m, H-10’) 
6.08 (s) 3.51 – 3.43 
(m) 
16g 9.36 (s) 8.35 (s) 7.81 (d, H-10’), 7.41 – 
7.37 (m, H-9’), 7.21 – 
7.15 (m, H-7’) 
6.00 (s) 3.54 – 3.46 
(m) 
16h 9.39 (s) 8.35 (s) 7.81 (d, H-6’), 7.38 (dd, 
H-10’), 7.22 – 7.13 (m, 
H-9’) 
5.99 (s) 3.52 – 3.46 
(m) 
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Table 2: Key signals in the 13C NMR spectra of the anilino-pyrimidine alcohols 16a-h 
Compound C-4’ 
(ppm) 
C-1’ 
(ppm) 
Aniline carbon atoms 
(ppm) 
C-3’ 
(ppm) 
C-3 
(ppm) 
C-4 
(ppm) 
16a 161.1 156.7 141.0 (C-5’), 130.1 (C-9’), 
124.0 (C-8’), 121.0 (C-7’), 
121.2 (C-6’), 117.7 (C-10’) 
88.1 71.8 59.6 
16b 161.8 157.6 139.5 (C-5’), 128.7 (C-7’ 
and C-9’), 122.5 (C-8’), 
119.9 (C-6’ and C-10’) 
87.7 72.1 60.0 
16c 161.6 157.1 152.5 (d, J = 241.4 Hz, C-
8’), 137.2 (d, J = 2.9 Hz, 
C-5’), 121.0 (C-6’), 119.9 
(d, J = 6.7 Hz, C-10’), 
119.0 (d, J = 20.0 Hz, C-
7’), 116.8 (d, J = 21.8 Hz, 
C-9’), 
88.4 72.3 60.2 
16d 162.2 156.1 139.6 (C-5’), 129.9 (C-9’), 
127.0 (C-8’), 123.6 (C-6’), 
122.5 (C-7’), 121.6 (C-10’) 
88.2 72.6 60.5 
16e 162.4 158.1 161.1 (C-7’ and C-9’), 
142.1 (C-5’), 98.6 (C-6’ 
and C-10’), 94.6 (C-8’) 
88.8 72.9 60.7 
16f 161.1 156.6 148.4 (dd, J = 243.3, 13.1 
Hz, C-7’), 144.1 (dd, J = 
240.8, 12.9 Hz, C-8’), 
136.5 (dd, J = 9.2, 2.5 Hz,  
C-5’), 116.8 (d, J = 17.7 
Hz,  C-9’), 115.3 (dd, J = 
5.7, 3.0 Hz,  C-10’), 108.1 
(d, J = 21.4 Hz,  C-6’) 
87.8 71.8 59.6 
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As can be seen from Tables 1 and 2, the key signals only shifted slightly when varying the 
aniline substituents. Some interesting NMR spectral features were observed for the 
synthesised compounds. For compounds 16c and 16f (Figure 2.1), the expected fluorine 
coupling to the carbon atoms and protons was evident in their NMR spectra. 
 
Figure 2.1: Chemical structures of compounds 16c and 16f 
Carbon-fluorine coupling constants (JC-F) have been reported in literature; 1JC-F ~ 245 Hz, 
2JC-F ~ 21 Hz, 3JC-F ~ 8 Hz and 4JC-F ~ 3 Hz. From the 13C NMR spectrum of compound 16f 
two similar doublet of doublet signals were observed at δ 148.4 and δ 144.1 with JC-F = 243.3 
and 13.1 Hz and JC-F = 240.8 and 12.9 Hz, respectively. Comparing the observed JC-F to the 
known literature values, the observed JC-F values corresponded with 1JC-F and 2JC-F. That 
then meant that each of the signals could either be assigned to C-7’ or C-8’. Using the 
heteronuclear multiple bond correlation (HMBC) experiment, the signal at δ 144.1 had a long 
range correlation with H-10’ but no correlation was observed with the signal at δ 148.4. 
Correlation between carbon atoms and protons separated by three bonds is more likely to be 
observed than the four bond correlation. Hence the signal at δ 144.1 was assigned to be C-
8’ and C-7’ was assigned to the signal at δ 148.4. Assignment of the other carbon atoms was 
done with no difficulty: from the distortionless enhancement by polarization transfer (DEPT-
16g 162.4 158.2 149.2 (C-8’), 134.7 (C-5’), 
122.2 (C-10’), 122.0 (C-
6’), 120.3 (C-9’), 115.4 (C-
7’) 
88.2 72.9 60.7 
16h 161.8 157.7 148.7 (C-8’), 134.2 (C-5’), 
121.7 (C-10’), 121.5 (C-
6’), 119.8 (C-9’), 114.9 (C-
7’) 
87.7 72.3 60.2 
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135) experiment, the doublet of doublets at δ 136.5 was the only other quaternary carbon 
atom with fluorine splitting (JC-F = 9.2, 2.5 Hz) and was assigned to C-5’. C-6’, C-9’ and C-10’ 
were easily assigned using the heteronuclear single quantum correlation (HSQC) 
experiment. Interestingly C-6’ which was expected to be a doublet of doublets was observed 
as a doublet with JC-F = 21.4 Hz. No plausible conclusion was reached as to why C-6’ only 
coupled to the ortho fluorine and not to the meta one. The fluorine coupling to carbon atoms 
and protons was also seen for compounds 16g and 16h. 
2.1.4. The synthesis of 2-{2-[4-(3-bromophenylamino)pyrimidin-6-
yloxy]ethoxy}acetaldehyde 15a and analogues  
The next step towards the synthesis of pyrimidine ketoamide molecules was the oxidation of 
an alcohol 16a to an aldehyde 15a (Scheme 21). Oxidation of the alcohol 16a was initially 
attempted by stirring a solution of compound 16a in DCM in the presence of Dess–Martin 
periodinane (DMP) 35 (Scheme 22B) at room temperature overnight. 
 
Scheme 21: Reagents and conditions: DMP, DCM, r.t., overnight, no reaction 
DMP has been widely used for the oxidation of primary and secondary alcohols to aldehydes 
and ketones with no further oxidation of aldehydes to the carboxylic acid analogues being 
seen.63,64 We chose DMP over other commonly used oxidants because it was relatively easy 
to prepare and store, and it was readily soluble in organic solvents. DMP can easily be 
prepared from 2-iodoxybenzoic acid (IBX) 36 (Scheme 22A). 
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Scheme 22: Reagents and conditions: i. KBrO3, 2.0 M H2SO4, 65 °C, 2.5 h, 81%; ii. Ac2O, p-TSA, 
85°C – r.t., 2 h, 77%  
 TLC analysis of the reaction mixture indicated the formation of a new spot with an Rf value 
very similar to that of the starting material 16a. The reaction mixture was purified by silica gel 
column chromatography. The isolated organic material was submitted for 1H NMR 
spectroscopic characterisation and from the 1H NMR spectrum we observed a prominent 
singlet integrating for two protons at δ 4.21 which was characteristic of H-3 of 15a. 
Unfortunately, the aldehyde 15a was not the only compound observed from the 1H NMR 
spectrum: we also observed the DMP by-product. The reaction was repeated following the 
same procedure to see if the same results would be obtained and we still isolated a mixture 
of compound 15a and DMP by-product. Various other attempts were made to try and get 
pure 15a, but they unfortunately all led to the same undesirable results. These results 
contradicted what was reported in literature, which indicates that DMP oxidation by-products 
can be easily removed by simple workup procedures.  
Our next attempt to carry out the oxidation reaction was done using pyridinium 
chlorochromate (PCC) (Scheme 23, 37) as the oxidising agent. PCC 37 is a widely used 
oxidant for the oxidation of alcohols one step up the oxidation ladder: primary alcohols to 
aldehydes and secondary alcohols to ketones. Like DMP, PCC 37 is also known for its great 
advantage of not further oxidising the aldehydes to carboxylic acids.65 For this synthesis we 
added compound 16a and PCC 37 into a flask containing molecular sieves in DCM. The 
reaction mixture was stirred at room temperature overnight. The observed crude material 
looked like messy black tar. TLC analysis of the mixture did not indicate the presence of 
either the starting material 16a, the product 15a or any other newly formed organic 
compound.  
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The mechanism through which the oxidation of primary alcohols to aldehydes by PCC takes 
place is outlined in Scheme 23. Briefly, the chlorine atom on the chromium (IV) atom is 
displaced by the coordination of the hydroxy group. The chlorine atom then acts as a 
Brønsted base abstracting a proton from the newly formed chromate ester 38. That results in 
the formation of an aldehyde and the reduction of chromium(VI) to chromium(IV).  
 
Scheme 23: Oxidation of primary alcohols to aldehydes using PCC 
After unsuccessful oxidation of our alcohol 16a we then hypothesised that any of the oxygen 
and nitrogen atoms in our compound 16a could coordinate to chromium(IV) in step (i) of the 
PCC  oxidation. We hypothesised that our compound could then get locked into that 
complex such that no further reaction occur. No detailed investigation was conducted to 
validate this hypothesis but to escape the toxicity and messy workup linked to chromium we 
then decided to investigate other oxidation methods. 
For the next attempt we used a method described by Omura et al. where DMSO and 
trifluoroacetic anhydride (TFAA) are used as reagents for the oxidation of alcohols to 
aldehydes at temperatures lower than -50°C.66 We added TFAA in DCM dropwise to a 
solution of DMSO in DCM at -78°C. The reaction mixture was stirred for 30 min at -78°C, 
whereafter compound 16a was added and the yellow reaction mixture was stirred for a 
further 30 min. Triethylamine (TEA) was then added and the mixture was warmed to room 
temperature and stirred for 30 min. An interesting observation was that after TEA addition 
the colour of the reaction mixture turned from yellow to clear. This was a hopeful observation 
as the addition of TEA is supposed to give the desired aldehyde product. However, after 
stirring for about 15 min the reaction mixture became yellow again. The crude material was 
characterised by NMR spectroscopy. Although Omura et al. reported successful and high 
yielding oxidation of alcohols to aldehydes using this method, we unfortunately recovered 
starting material 16a. This was seen from the 1H NMR spectrum of the crude material where 
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we did not observe the significant aldehyde peak. Based on the observed colour changes, 
we speculated that the reaction may have reversed within the given time. The reaction was 
repeated to assess the effect of the reaction time and confirm the reversibility of the reaction. 
With regard to the observed colour changes the results were not reproducible: after TEA was 
added the reaction mixture remained yellow. 1H NMR spectroscopic analysis of the crude 
material clearly indicated the presence of starting material 16a.  
At this point we decided to investigate an oxidant that was easier to prepare and required 
simpler reaction conditions. For this investigation we used 2-iodoxybenzoic acid (IBX) 36 as 
an oxidant. IBX 36 is the precursor used for the preparation of DMP 35 (Scheme 22A), 
hence it has the same oxidising properties as DMP 35. IBX 36 has also been found to be 
effective when oxidising primary and secondary alcohols to their corresponding carbonyl 
compounds.64 IBX 36 was easily prepared from 2-iodobenzoic acid in the presence of 
potassium bromate and sulfuric acid. We used a procedure described by Boeckman et al. 63: 
they reported a yield of 98% while we obtained an isolated yield of 81% (Scheme 22A).  The 
main drawback observed with IBX 36 is its limited solubility as it is insoluble in most organic 
solvents but it readily dissolves in DMSO.63,64  
IBX was added to a solution of 16a in DMSO and the reaction was stirred at room 
temperature. Upon TLC analysis a very small Rf shift was observed between the product and 
the starting material, which made it unclear whether the reaction had taken place or not. 
Despite the uncertainty the reaction was added to DCM and was washed three times with 
water and once with brine to yield 15a as an orange solid in 86% yield. The most prominent 
evidence of the formation of product 15a was observed in its 1H and 13C NMR spectra. The 
most significant change was the appearance of a singlet at δ 4.18 which integrated for two 
protons due to H-3. Furthermore, in the 13C NMR spectrum a prominent aldehyde peak was 
observed at δ 200.4. This confirmed that the oxidation of the alcohol to an aldehyde had 
indeed taken place. The IR spectrum also indicated the absence of the OH group at 
3378 cm-1 and a new C=O stretch was observed at 1606 cm-1 which was characteristic of the 
aldehyde. Conclusive evidence was then obtained from the HRMS of 15a where a molecular 
ion peak was observed at m/z 352.0291 which was in agreement with the calculated [M+H]+ 
for C14H15BrN3O3  of 352.0281. We then synthesised five other analogues 15b-f using IBX as 
an oxidant (Scheme 24) and, as expected, the NMR spectra were very similar. Compounds 
16g & h were unfortunately isolated in very low yields, hence we could not oxidise them to 
their aldehyde analogues 15g & h. The key diagnostic signals of the aldehyde analogues 
15a-f are tabulated in Tables 3 and 4 below. 
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15b:  R = H, 66% 
15c:      = 3-chloro-4-fluoro, 86% 
15d:      = 3-ethynyl, 62% 
15e:      = 3,5-dimethoxy, 61% 
15f:       = 3,4-difluoro, 90% 
Scheme 24: Reagents and conditions: IBX, DMSO, r.t., overnight 
From the isolated yields we observed that the reaction favoured substrates with electron 
deficient anilines. The highest isolated yield of 90% was obtained with the most electron 
deficient 3,4-difluoroaniline and the lowest isolated yield of 61% was obtained with the most 
electron rich 3,4-dimethoxyaniline.  
Table 3: Key signals in the 1H NMR spectra of the anilino-pyrimidine aldehydes 15a-f 
Compound H-4 (ppm) H-3 (ppm) 
15a 9.74 (s) 4.19 (s) 
15b 9.73 (s) 4.16 (s) 
15c 9.72 (s) 4.18 (s) 
15d 9.73 (s) 4.18 (s) 
15e 9.73 (s) 4.18 (s) 
15f 9.73 (s) 4.18 (s) 
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Table 4: Key signals in the 13C NMR spectra of the anilino-pyrimidine aldehydes 15a-f 
Compound C-4 (ppm) C-3 (ppm) 
15a 200.3 76.7 
15b 200.4 76.6 
15c 200.3 76.7 
15d 200.3 77.6 
15e 200.7 76.7 
15f 200.3 76.7 
 
The 1H and 13C NMR spectroscopic analysis (Tables 3 and 4) indicated that the aniline 
substituents had no significant effect on the key signals. The observed chemical shifts were 
similar for all compounds. 
2.1.5. The synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanamide 14a and analogues 
Multicomponent coupling reactions (MCRs) have been widely applied in organic chemistry 
and more specifically in medicinal chemistry. The Passerini reaction is one of the influential 
MCRs that were discovered decades ago.67 The Passerini reaction is also the first member 
of the isocyanide-based MCRs; it is a three component MCR that makes use of an 
aldehyde/ketone, a carboxylic acid and an isocyanide to form α-acyloxy-carboxamides.67,68 
The α-acyloxy-carboxamides can then be hydrolysed to give the useful α-hydroxyamides like 
compound 14a (Scheme 25).  
 
  
Scheme 25: Reagents and conditions: AcOH, EtOAc/DCM, r.t., 24 h. K2CO3, MeOH/H2O, r.t., 3 h, 
59% 
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For this synthesis we applied the Passerini reaction to give the α-acyloxy-carboxamide 
adduct 39a (Scheme 26) which was then hydrolysed under basic conditions to give the 
desired product 14a. Initially compound 15a was dissolved in DCM and diluted with EtOAc, 
AcOH and isopropyl isocyanide were then added and the reaction mixture was stirred at 
room temperature for 24 h. Scheme 26 outlines the mechanism through which the reaction 
occurrs to form 39a based on the mechanism that was proposed by Ugi.67  
 
Scheme 26: Reagents and conditions: i. K2CO3, MeOH/H2O, r.t., 3 h, 59% 
The reaction is believed to proceed through a cyclic transition state which can either be five-
membered or seven-membered depending on which oxygen atom of the carboxylic acid 
participates.67 From Scheme 26 we only indicated the five-membered transition state where 
the hydroxyl oxygen participates, the seven-membered transition state would form when the 
carbonyl oxygen is participating. After stirring for 24 h we had afforded the α-acyloxy-
carboxamide intermediate 39a. Intermediate 39a was not isolated, it was hydrolysed by 
dissolving in methanol in the presence of a solution of potassium carbonate (K2CO3) in water 
to afford the desired product 14a in 59% yield.  
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Successful synthesis of compound 14a was confirmed by NMR spectroscopic and HRMS 
analysis. In addition to the absence of an aldehyde peak from the 1H NMR spectrum of 14a, 
there were four main characteristic signals that differentiated it from the 1H NMR spectrum of 
the starting material 15a. The first one was the presence of two doublets at δ 1.16 and 
δ 1.13 that in total integrated for six protons. This was characteristic of H-7, where each 
methyl group coupled to H-6. Another characteristic peak was a multiplet, which closely 
resembled a septet, at δ 4.11 – 4.02 integrating for one proton. This signal was characteristic 
of H-6: it closely resembled a septet because it was coupled to the six methyl protons. One 
other characteristic peak was a triplet integrating for one proton at δ 4.22 and that was 
characteristic of H-4. Finally, the presence of a new NH signal at δ 6.68 confirmed that the 
reaction had indeed afforded the desired product 14a. Further confirmation was obtained 
from the 13C NMR spectrum. Firstly, no aldehyde signal was observed; instead there was a 
new signal at δ 170.6 that coupled to H-4 as shown by the HMBC experiment, hence it was 
assigned to C-5. We also observed C-4 at δ 70.3, C-6 at δ 41.2 and C-7 at δ 22.7. We 
obtained conclusive confirmation from the HRMS spectrum of 14a, as a molecular ion peak 
was observed at m/z 439.0975, which was in good agreement with the calculated [M+H]+ for 
C18H24BrN4O4 of 439.0963. Five other analogues 14b-f were synthesised using this method 
(Scheme 27) and Tables 5 and 6 summarise the characteristic signals of the α-
hydroxyamides 14a-f. As can be seen from these tables the aniline substituents did not have 
any significant effect on the chemical shifts of the α-hydroxyamide group.  
 
14b:  R = H, 36% 
14c:      = 3-chloro-4-fluoro, 60% 
14d:      = 3-ethynyl, 39% 
14e:      = 3,5-dimethoxy, 37% 
14f:       = 3,4-difluoro, 34% 
Scheme 27: Reagents and conditions: AcOH, EtOAc/DCM, r.t., 24 h. K2CO3, MeOH/H2O, r.t., 3 h 
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Table 5: Key signals in the 1H NMR spectra of the α-hydroxyamides 14a-f 
Compound NH (ppm) H-4 (ppm) H-6 (ppm) H-7 (ppm) 
14a 6.68 (d) 4.22 (t) 4.11 – 4.02 (m) 1.15 (d) and 1.13 (d) 
14b 6.63 (s) 4.19 (t) 4.11 – 4.02 (m) 1.14 (d) and 1.12 (d) 
14c 6.59 (d) 4.18 (t) 4.12 – 4.02 (m) 1.16 (d) and 1.14 (d) 
14d 6.66 (d) 4.23 – 4.13 (m) 4.10 – 4.03 (m) 1.15 (d) and 1.13 (d) 
14e 6.60 (d) 4.18 (t) 4.11 – 4.03 (m) 1.15 (d) and 1.13 (d) 
14f 6.66 (d) 4.18 (t) 4.11 – 4.03 (m) 1.15 (d) and 1.13 (d) 
 
Table 6: Key signals in the 13C NMR spectra of the α-hydroxyamides 14a-f 
Compound C-5 (ppm) C-4 (ppm) C-6 (ppm) C-7 (ppm) 
14a 170.5 70.3 41.2 22.7 
14b 170.5 70.1 41.1 22.6 
14c 170.4 70.2 41.2 22.6 
14d 170.5 70.3 41.2 22.7 
14e 170.4 70.1 41.2 22.6 
14f 170.5 70.4 41.2 22.7 
 
The pH of the reaction mixture when doing the hydrolysis step was found to be crucial for 
successful synthesis of 14a. In instances where some AcOH hadn’t reacted with K2CO3, both 
compounds 14a and 39a were isolated. For successful hydrolysis the pH had to be basic.  In 
instances where compound 39a was isolated, from the 1H NMR spectrum it was 
characterised by a prominent singlet at δ 2.16 integrating for three protons. Initially the signal 
had been thought to be due to the presence of washing acetone. However, from the low 
resolution mass spectrum of 39a two significant signals were observed at m/z 483.3 and 
481.3; those were in agreement with the calculated [M+H]+ for the two bromine isotopes of 
C20H26BrN4O5. After this analysis the signal was then assigned to H-8. One other significant 
change observed was the downfield shift of the H-4 triplet from δ 4.22 to δ 5.28 when 
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comparing compounds 14a and 39a. The carbonyl group in conjugation with the oxygen 
atom reduced the electron donation effect of the oxygen by withdrawing electrons from it. 
Hence the observed downfield shift of H-4 in compound 14a when compared to 39a.   
2.1.6. The synthesis of 2-oxo-N-isopropyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanamide 13a and analogues 
The final step towards the synthesis of pyrimidine ketoamides was the oxidation of the α-
hydroxy amides 14a-f using IBX in DMSO (Scheme 28). As per the procedure described in 
2.1.4, IBX was added to a solution of compound 14f in DMSO (Scheme 29A). The reaction 
mixture was stirred at room temperature overnight. The 1H NMR spectrum of the crude 
material clearly confirmed that the oxidation had occurred. This was demonstrated by the 
presence of a singlet that integrated for two protons at δ 4.91; this signal was being 
characteristic of H-3.  
 
 
  
13a:  R = 3-bromo  
13b:      = H, 70% 
13c:      = 3-chloro-4-fluoro, 84% 
13d:      = 3-ethynyl, 76% 
13e:      = 3,5-dimethoxy, 78% 
13f:       = 3,4-difluoro 
 
Scheme 28: Reagents and conditions: IBX, DMSO, r.t., overnight 
From the 1H NMR spectrum of the crude material, we could see that the compound was not 
pure, as some unknown minor signals were observed. TLC analysis of the crude material 
indicated three well separated spots of equal quantity, judging from the intensity of the spots. 
The crude material was then purified by silica gel chromatography and the collected spots 
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were submitted for 1H NMR spectroscopic characterization. The 1H NMR spectra indicated 
that the first and the third spots appeared to be the same compound and no insightful 
information could be deduced from the middle spot.  
Interestingly, the 1H NMR spectra of the first and third spot did not indicate the presence of 
the desired product 13f, instead they indicated the presence of an unknown compound. First 
of all, the singlet at δ 4.91 that was assigned to H-3 was no longer observed. Two other 
signals that were no longer observed were: the multiplet at δ 4.12 – 3.96 assigned to H-6 
and the doublet at δ 1.20 assigned to H-7. This observation suggested that the desired 
product had decomposed. We hypothesised that chain cleavage had occurred to yield 
compound 40 (Scheme 29B). 
 
Scheme 29: Pyrimidine ketoamide cleavage 
Although not clearly resolved, the 1H NMR spectrum of the cleavage product had signals 
very similar to those of the expected product 13f in the aromatic region. The significant 
difference was observed in the aliphatic region: multiplets each integrating for two protons 
were observed at δ 4.45 – 4.43 and δ 3.99 – 3.84. The two signals were assigned to H-1 and 
H-2, respectively. The observed 1H NMR spectrum was in good agreement with the 
proposed structure of the cleavage product.  
In an effort to investigate the decomposition, the reaction was repeated and the crude 
material was submitted for 1H NMR spectroscopic analysis. The 1H NMR spectrum (Figure 
2.2) indicated a singlet at δ 4.90 characteristic of H-3 which confirmed that the oxidation had 
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taken place. Other observed signals that will be important for this discussion were: the 
multiplets each integrating for two protons at δ 4.56 – 4.52 and δ 3.90 – 3.85 characteristic 
of H-1 and H-2, respectively; and another multiplet also integrating for two protons at δ 4.09 
– 3.99 which was characteristic of H-6. Since this was a crude sample, there were minor 
unknown signals that were observed in the spectrum and they were thought to be due to 
impurities. 
The sample was then kept in the NMR tube at room temperature. After 24 h the sample was 
resubmitted for 1H NMR spectroscopic analysis and not much change was observed from 
the original spectrum. We then left the sample in the NMR tube at room temperature for a 
further eight days and upon 1H NMR spectroscopic analysis of the sample we observed that 
there was a reaction/decomposition occurring. The decomposition was suggested by the 
progressive increase in intensity of the minor peaks surrounding the two multiplets at δ 4.56 
– 4.52 and δ 3.90 – 3.85 (Figure 2.3). We then left the sample for a further eleven days and 
it was clearly evident that a reaction/decomposition was taking place (Figure 2.4).  
 
 
Figure 2.2: Initial 1H NMR spectrum of the crude product containing 13f  
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Figure 2.3: 1H NMR spectrum of the crude mixture of 13f and 40 forming after nine days 
 
Figure 2.4: 1H NMR spectrum of the crude mixture of 13f and 40 forming after twenty days 
The main observation to be made from these figures is how the minor peaks intensify over 
time. The fact that the compound decomposed only very slowly upon standing at room 
temperature gave us the idea that silica gel might be catalysing the decomposition reaction 
during purification. This theory was supported by the fact that we were not able to isolate the 
desired product 13f when purifying our material by silica gel chromatography. The exact 
mechanism by which the decomposition took place was not fully investigated. Other 
purification methods like recrystallization and trituration were tried, but none of them resulted 
in the pure compound 13f. Taking into account the very small amount of sample available, 
we were unable to test numerous purification methods. 
Five other analogues 13a-e were synthesised using this method (Scheme 28). After the 
observation that the desired compound was cleaved upon purification by silica gel column 
chromatography, compounds 13b-e were fully characterised without further purification. The 
yields reported in Scheme 28 are for the crude product. Successful synthesis of the 
compounds was first confirmed by NMR spectroscopic analysis. A singlet integrating for two 
protons was observed at δ 4.90 for all products and this was the most significant signal 
56 
 
characteristic of H-3. Further confirmation was obtained from HRMS analysis. The calculated 
and the observed molecular ion peak masses (m/z) are tabulated in Table 7. 
Table 7: Calculated and observed masses (m/z) for compounds 13b-e 
Compound [M+H]+ Calculated mass (m/z) Observed mass (m/z) 
13b C18H23N4O4 359.1709 359.1714 
13c C18H21ClFN4O4 411.1222 411.1230 
13d C20H23N4O4 383.1700 383.1714 
13e C20H27N4O6 419.1907 419.1925 
 
In an attempt to avoid the cleavage reaction seemingly caused by silica gel, an alternative 
purification of compound 13a by high performance liquid chromatography (HPLC) using a 
C18 reversed phase column was tested. A mobile phase consisting of acetonitrile and water 
was used for the analysis which gave two broad, well-resolved peaks for our crude product. 
The two compounds were collected after separation by HPLC and were characterised by 1H 
NMR spectroscopy. 
No significant information could be obtained from the 1H NMR spectrum of the less polar 
compound. From the 1H NMR spectrum of the more polar compound, significant changes 
were only observed in the aliphatic region: two multiplets each integrating for two protons 
were observed at δ 4.51 – 4.44 and δ 3.96 – 3.89. To our surprise, these results revealed 
that the more polar compound was similar to the undesired cleaved compound 40. In light of 
the observation that purification by either silica gel or C18-bonded silica led to the isolation of 
the cleaved product, it became clear that the cleavage reaction was not due only to silica 
gel. Unfortunately, we could not investigate this reaction any further due to time constraints.  
2.1.7. Preliminary biological evaluation of pyrimidine ketoamides 
A selection of the anilino-pyrimidine compounds that contained an electrophilic carbon atom, 
13-16, were evaluated for preliminary anticancer activity in an in vitro MTT assay on five 
different cancer cell lines. The assays were done by Dr Leonie Harmse (Wits School of 
Pharmacy and Pharmacology). The preliminary evaluation was done on the Caco-2 
(colorectal cancer), MCF7 (breast cancer), SF268 (glioblastoma), A549 (lung cancer) and 
H1975 (lung cancer) cell lines. All the cells were exposed to 5 and 50 μM of our test 
compounds to determine those with cell viability of less than 50% after 48 h exposure. Four 
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repeat experiments were done for each cell assay and no activity was observed for the 
colorectal cancer, A549 and H1975 lung cancer cell lines.  
Of all the compounds tested for in vitro anticancer activity, compounds 15a and 15c (Figure 
2.5) were found to be the most active. However, these compounds were only active at high 
concentrations (50 μM) on the MCF7 breast cancer and SF268 glioblastoma cell lines 
(Figures 2.6 and 2.7).  
 
                                              
Figure 2.5: Anilino-pyrimidine analogues that displayed preliminary activity against the MCF7 breast 
cancer and glioblastoma cell lines. 
 
 
Figure 2.6: Evaluation of our test compounds against MCF7 breast cancer cell line 
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As can be seen in Figure 2.6, compound 15c was found to be the most active against the 
MCF7 breast cancer cell line, and the IC50 value of this compound was determined to be 
48.74 μM.  
 
Figure 2.7: Evaluation of our test compounds against the glioblastoma cell line 
Figure 2.7 indicates that compounds 15a and 15c were active against the glioblastoma cell 
line. The most active test compound was found to be 15c and an IC50 value of 30.75 μM was 
determined.  
Therefore, from our series of compounds the aldehyde warhead was the one that proved to 
be the most active. This could be due to the fact that aldehydes can also participate in 
reversible binding with the cysteine thiol in a similar mechanism to the one described in 
Scheme 2 (Chapter 1) for the ketoamide warhead. Overall, the results indicated that our 
compounds were not very active against the cancer cell lines tested. Even though 
compounds 15a and 15c showed some activity in the cell-based assays, the mode of 
inhibition of cell growth has not been tested. To determine whether or not they are active 
against EGFR, their activity in an enzymatic (EGFR) inhibition assay would need to be 
evaluated. 
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2.2. Attempted synthesis of pyrimidine ketoesters 
In another aspect of this project we attempted the synthesis of pyrimidine ketoesters. Based 
on literature results we realised that we could access the ketoester functional group from our 
already synthesised aldehydes 15a-b. Scheme 5 in 1.5.2 outlined the retrosynthetic strategy 
towards the desired ketoester molecules. Scheme 30 below outlines the synthetic plan. The 
synthesis began with the preparation of cyanohydrins 22a-b. These compounds were then 
subjected to hydrolysis and esterification conditions in an attempt to obtain the desired α-
hydroxy esters 21a-b. The final step was planned to be the oxidation of the α-hydroxy ester 
compounds 21a-b to yield the final ketoesters 20a-b.  
 
 
20a:  R = 3-bromo  
20b:      = H 
Scheme 30: Outline of the proposed synthetic route towards pyrimidine ketoesters 20a-b  
2.2.1. The synthesis of 2-hydroxy-3-{2-[4-(3-bromophenylamino)pyrimidin-6-
yloxy]ethoxy}propanenitrile 22a and analogue 
The attempt towards synthesis of α-ketoesters began with the synthesis of cyanohydrin 22a 
(Scheme 31). Cyanohydrins have been identified as useful intermediates for the synthesis of 
α-hydroxy aldehydes, ketones and esters. Cyanohydrins can be prepared by a reaction 
which involves an aldehyde or a ketone, sodium bisulfite (NaHSO3) and excess amounts of 
sodium cyanide (NaCN) or potassium cyanide (KCN).68 We preferred this method as it does 
not use the hazardous hydrogen cyanide. 
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Scheme 31: Reagents and conditions: NaHSO3, MeOH/H2O, 0°C, 2 h. KCN, H2O, r.t., overnight, 19% 
The reaction is believed to proceed by the mechanism postulated in Scheme 32. The first 
step of this reaction is the formation of the bisulfite addition product. This reaction is 
reversible and addition of KCN reverses the formation of the bisulfite adduct regenerating 
the aldehyde 15a. The cyanide anion attacks the carbonyl carbon to give the cyanohydrin 
anion, which abstracts a proton from the bisulfite compound to give the desired cyanohydrin 
22a. In order to carry out the reaction, a solution of aldehyde 15a in MeOH was added to a 
solution of NaHSO3 in H2O at 0°C. The isolated yield of product 22a was very low, only 19% 
and this was postulated to be due to the reversible nature of the cyanohydrin formation 
reaction.  
The synthesis of compound 22a was confirmed by NMR spectroscopy and HRMS. The 1H 
NMR spectrum of 22a did not show the aldehyde signal. A singlet integrating for one proton 
was observed at δ 4.69 and this was characteristic of OH. One other characteristic signal 
was a triplet integrating for one proton at δ 4.60 and from the COSY experiment this signal 
was coupled to H-3. This signal was then assigned to H-4. Clear evidence of the formation of 
the desired product was obtained from the 13C NMR spectrum where a signal at δ 118.2 was 
observed. This signal was characteristic of a nitrile carbon atom, hence it was assigned to C-
5. The signal characteristic of C-4 was observed at δ 60.8. Conclusive confirmation was 
obtained from HRMS as a molecular ion peak was observed at m/z 379.0400 which was in 
good agreement with the calculated [M+H]+ for C15H16BrN4O3 of 379.0390.  
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Scheme 32: Proposed mechanism for the formation of cyanohydrin 22a 
Despite the low isolated yield, one other analogue 22b was successfully synthesised using 
the procedure (Scheme 33). Similar to compound 22a, the most significant change in the 1H 
NMR spectrum of cyanohydrin 22b was the formation of a multiplet at δ 3.95 – 3.83 which 
was due to the hydroxyl proton. H-4 was observed as a triplet at δ 4.60. The prominent nitrile 
carbon atom C-5 was observed as a signal at δ 118.4 in the 13C NMR spectrum. The C-4 
signal was observed at δ 60.7. From HRMS, we observed a molecular ion peak at m/z 
301.1295 which corresponded with the calculated [M+H]+ for C15H17N4O3 of 301.1295. 
 
Scheme 33: Reagents and conditions: NaHSO3, MeOH/H2O, 0°C, 2 h. KCN, H2O, r.t., overnight, 24% 
62 
 
2.2.2. The attempted synthesis of methyl 2-hydroxy-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanoate 21a and 21b  
The next step towards ketoester synthesis was the conversion of the nitrile group to an ester 
by hydrolysis followed by doing an esterification reaction to afford the desired product. A 
variety of hydrolysis and esterification procedures have been described in the literature. We 
followed a procedure that was described by Matsuda et al.,70 mainly because they reported 
high yields when doing this hydrolysis followed by esterification reaction and the substrates 
they were working on were similar to ours. 
 
Scheme 34: Reagents and conditions: H2SO4, MeOH/H2O, 60 – 70°C, 4 h. MeOH, reflux, overnight. 
For this synthesis; a solution of compound 22a (Scheme 34) in MeOH/H2O was added 
dropwise to a round bottomed flask containing 98% sulfuric acid.  This mixture was heated 
for 1 h at 60°C, thereafter it was heated at 70°C for a further 3 h. At this point we assumed 
that the hydrolysis reaction to afford the carboxylic acid derivative of compound 21a was 
complete. We did not attempt to isolate the carboxylic acid but proceeded directly to the next 
step. Excess MeOH was added and the reaction was refluxed overnight in an attempt to 
carry out the esterification reaction. The product was isolated as a light yellow solid in 12% 
yield. 
The isolated yield was very low compared to the reported literature yield of 88%.70 Various 
factors could contribute to the very low isolated yields, but one interesting observation that 
was made was that upon purification some of aldehyde 15a was recovered. Starting material 
22a was purified prior to doing this reaction, and the presence of the aldehyde 15a in the 
final reaction mixture suggested that our reaction conditions were reversing cyanohydrin 
formation to give the aldehyde 15a.  
The isolated product was characterised by NMR spectroscopy. From the 1H NMR spectrum 
the main difference observed was the presence of a singlet at δ 3.39 integrating for six 
protons. This was not in correspondence with the expected results of the desired product 
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21a: for compound 21a the singlet would have to integrate for three protons and it would be 
characteristic of H-6. No major shift was observed for the signal characteristic of H-4, it was 
observed as a triplet at δ 4.52. From the 13C NMR spectrum it was clear that the nitrile group 
had reacted as the nitrile carbon signal at δ 118.2 was no longer observed. Interestingly, 
however, it was observed from the HSQC experiment that the C-4 signal had shifted to a 
region characteristic of an acetal functional group. The signal was observed at δ 102.8 and it 
led to the hypothesis that under our reaction conditions we had formed an acetal instead of 
the α-hydroxy ester.  
Scheme 35 outlines the proposed mechanism for the formation of the acetal compound 41a. 
It appears that under our reaction conditions the cyanohydrin 22a eliminates CN- to form the 
aldehyde 15a. This explains why we recovered aldehyde 15a during purification by silica gel 
chromatography. In the presence of an acid and methanol, the aldehyde then undergoes 
functional group interconversion to form an acetal as shown in Scheme 35.  
This theory was supported by the HRMS analysis of compound 41a as a molecular ion peak 
was observed at 398.0710 which was in good agreement with the calculated [M+H]+ for 
C16H21BrN3O4 of 398.0708. 
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Scheme 35: Proposed mechanism for the formation of acetal 41a 
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Compound 22b was subjected to the same reaction conditions and the same results were 
observed (Scheme 36). The formation of the acetal 41b was confirmed by NMR 
spectroscopy and HRMS. From the 1H NMR spectrum H-5 was observed at δ 3.39 as a 
singlet integrating for six protons. From the 13C NMR spectrum the significant acetal carbon 
atom, C-4, was observed at δ 103.3. Conclusive confirmation was obtained from HRMS, 
where we observed a molecular ion peak at m/z 320.1605 which corresponded with the 
calculated [M+H]+ for C16H22N3O4 of 320.1608.  
 
 
Scheme 36: Reagents and conditions: H2SO4, MeOH/H2O, 60 – 70°C, 4 h. MeOH, reflux, overnight, 
25% 
Alternative reactions would have to be investigated for successful synthesis of compounds 
21a-b. We were, unfortunately, unable to investigate other reactions due to time constraints. 
Hence, the oxidation of compounds 21a-b to give the target pyrimidine ketoesters 20a-b 
could not be carried out (Scheme 30).  
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CHAPTER 3: CONCLUSIONS AND FUTURE WORK 
The primary aim of this project was to synthesise potential covalent-reversible EGFR-TKIs 
for anticancer treatment. As a novel class of EGFR-TKIs we chose to synthesise pyrimidine 
ketoamide and ketoester molecules. The synthesis of the pyrimidine ketoamide compounds 
began with the protection of one hydroxy group of diethylene glycol using tetrahydropyran. 
The resultant product was coupled with 4,6-dichloropyrimidine to afford 4-chloro-6-{2-[2-
(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethoxy}pyrimidine 31 in 54% yield. 
 
Scheme 37: Reagents and conditions: (i) conc. HCl, 2-propanol, reflux, overnight; (ii) conc. HCl, 2-
propanol, reflux, 48 h;  (iii) IBX, DMSO, r.t., overnight; (iv) AcOH, EtOAc/DCM, r.t., 24 h. K2CO3, 
MeOH/H2O, r.t., 3 h; (v) IBX, DMSO, r.t., overnight. 
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Initially, the deprotection step (i) and amination reaction in step (ii) were done over one step 
under acidic conditions. The deprotection of THP-protected alcohols under acidic conditions 
is a well-known reaction, but it was quite interesting to observe that the acid catalysed the 
cross-coupling reaction in the exact mechanism. This approach was an advantage as we 
could do two reactions over step, however, the isolated yields were very low. This was due 
to the various side products that would form when the two transformations were done as 
one; hence we resorted to doing the deprotection and amination reaction as two separate 
steps.  
The deprotection of the hydroxy group of 4-chloro-6-{2-[2-(tetrahydro-2H-pyran-2-
yloxy)ethoxy]ethoxy}pyrimidine was done under acidic conditions in step (i) (Scheme 37)  
producing the desired 2-[2-(4-chloropyrimidin-6-yloxy)ethoxy]ethanol 34  in a fairly good 63% 
yield. We then did the amination reaction between 2-[2-(4-chloropyrimidin-6-
yloxy)ethoxy]ethanol 34 and various aniline substrates 19, step (ii) (Scheme 37). Various 
reaction conditions were tried for this coupling reaction: base catalysed, Pd catalysed and 
acid catalysed amination. To our surprise the acid catalysed amination gave the best yields 
for almost all anilines (52-75%), with the exception of three anilines. The two sterically 
hindered anilines 2-chloro-4-((3-fluorobenzyl)oxy)aniline 19g (13%) and 3-chloro-4-((3-
fluorobenzyl)oxy)aniline 19h (9%) gave very poor yields, this was speculated to be due to 
steric effects. The amination reaction products 16 were then subjected to oxidation in step 
(iii) using IBX to yield their aldehyde derivatives 15 in good yields (61-90%). After successful 
synthesis of the aldehyde derivatives, the Passerini reaction was then employed using the 
aldehydes 15, acetic acid and isopropyl isocyanide; to yield the desired α-hydroxy amides 14 
(step (iv)). The final step of this synthesis was the oxidation of the α-hydroxy amide system 
using IBX to afford the targeted α-ketoamides 13. 
 
In an attempt to purify the α-ketoamide compounds we used a silica gel column, but we 
unfortunately only isolated an unexpected product 40 (Scheme 38). The observed cleavage 
reaction was hypothesised to be induced by silica gel, hence we attempted to purify the 
ketoamide compound using an HPLC C18 column. Unfortunately, we still isolated the 
unexpected compound 40. In future, it would be valuable to determine whether the cleavage 
reaction has anything to do with purification, or if it is self-destruction of the compounds. 
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Scheme 38: Pyrimidine ketoamide cleavage reaction 
In the second part of this project we attempted to synthesise pyrimidine ketoester 
compounds (Scheme 39). The synthesis began from the already synthesised aldehyde 15, 
which was subjected to functional group conversion in step (i) to give the cyanohydrin 22 
using potassium cyanide. In an attempt to produce the α-hydroxy ester 21, compound 22 
was subjected to acidic conditions in methanol in step (ii). Although other researchers have 
reported success with this kind of reaction in literature, we unfortunately did not get the 
desired product 21. Instead, we isolated the acetal 41 of the original aldehyde. This 
observation was a result of the cyanohydrin 22 undergoing an elimination of cyanide to give 
the original aldehyde. In the presence of excess methanol and acid the aldehyde was then 
converted to the acetal 41. It would be necessary in future to investigate other methods that 
could successfully produce the α-hydroxy ester compound 21. Alternatively, biocatalysts 
such as nitrilase could be used to directly convert the cyanohydrin 22 to the carboxylic acid 
which, after esterification, would give the targeted α-ketoester 20, step (iii). 
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Scheme 39: Reagents and conditions: (i) NaHSO3, MeOH/H2O, 0°C, 2 h. KCN, H2O, r.t., overnight (ii) 
H2SO4, MeOH/H2O, 60 – 70°C, 4 h. MeOH, reflux, overnight 
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In a preliminary biological evaluation, a selected number of the anilino-pyrimidine  analogues 
were assessed for anticancer activity in an in vitro MTT assay on five different cell lines. In 
the MCF7 (breast cancer) screen, only the aldehyde 15c was found to display activity at 50 
µM with an IC50 = 48.74 µM. In the SF268 (glioblastoma) screen, the aldehydes 15a and 15c 
were found to be active at 50 µM, aldehyde 15c was found to have an IC50 = 30.75 µM. 
What was interesting was that none of our pyrimidine ketoamide compounds were active; 
this then brought up the intriguing question of whether the observed poor stability of the 
ketoamide compounds had an effect on their activity. It would also be advisable that the 
pyrimidine ketoamide compounds be fully investigated with regards to their stability prior to 
sending them for biological evaluation.   
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CHAPTER 4: EXPERIMENTAL SECTION 
 
4.1. General procedures 
 
4.1.1. Solvents and reagents purification 
All reagents and solvents used for reactions were purchased from Sigma-Aldrich (South 
Africa), Merck KGaA (South Africa) and Associated Chemical Enterprises (South Africa); and 
were used without further purification. When necessary, solvents were distilled over 
appropriate drying mediums under a nitrogen atmosphere. Tetrahydrofuran (THF) was 
distilled from sodium wire using benzophenone as an indicator. Dichloromethane (DCM) was 
distilled from calcium hydride. 
Solvents for preparative chromatography and washing acetone were purchased from CC 
Imelmann (South Africa). 
4.1.2. Chromatography 
Thin-layer chromatography (TLC) was done on aluminium-backed Merck silica gel 60 F254 or 
Macherey-Nagel silica gel 60 UV254. Preparative TLC was done on glass-backed 1000 µm or 
1500 µm Analtech silica gel GF 20 × 20 cm UV254 plates.  For preparative column 
chromatography, Sigma-Aldrich silica gel 60 was used as the adsorbent. The mesh particle 
size was 70 – 230 for conventional gravity chromatography and 230 – 400 for flash 
chromatography. Dichloromethane and methanol mixtures were used as the mobile phase. 
High performance liquid chromatography (HPLC) was performed on a Thermo Scientific 
UHPLC system using a C18 reversed phase column. 
4.1.3. Spectroscopic and physical data 
Melting points were obtained on a Stuart SMP10 melting point apparatus and are 
uncorrected. 
Hydrogen nuclear magnetic resonance (1H NMR) spectra were acquired on a Bruker 300, 
400 or 500 MHz spectrometer in the specified deuterated solvents. For spectra recorded in 
deuterated chloroform (CDCl3), chemical shifts are reported in parts per million (ppm) 
relative to the internal tetramethylsilane (TMS) standard. For other deuterated solvents, the 
residual solvent signal was used as a reference. The 1H NMR spectra chemical shifts are 
reported as, value (splitting pattern, coupling constant(s) where applicable, number of 
protons, assignment). Carbon nuclear magnetic resonance (13C NMR) spectra were 
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acquired on the same instruments in the specified deuterated solvents. Chemical shifts are 
reported in ppm relative to the residual solvent signal.  The 13C NMR spectra chemical shifts 
are reported as, value (splitting pattern where applicable, coupling constant(s) where 
applicable, assignment). Coupling constant values are recorded in hertz (Hz). For all 
experiments the probe temperature was 300K.  
Infrared (IR) spectra were obtained on a Bruker Tensor-27 Fourier Transform spectrometer. 
High resolution mass spectrometry (HRMS) analysis was performed on a Bruker Compact 
Q-TOF high resolution mass spectrophotometer. Low resolution mass spectrometry (LRMS) 
was performed on an Advion expressionL compact mass spectrometer.  
4.1.4. Other general procedures 
For bromine (Br) or chlorine (Cl) containing compounds two molecular ion peaks are 
observed, the M+ and the (M+2)+ peaks. The M+ peak is due to the 79Br or 35Cl isotopes, 
while the (M+2)+ peak is due to the 81Br or 37Cl isotopes. The m/z values reported in the 
following sections are for compounds containing the 79Br or 35Cl isotopes.  
The numbering on compounds does not follow the official IUPAC rules. The atoms were 
numbered to allow for simpler characterisation assignments. 
4.2. Synthesis of 2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethanol 17 59 
                                             
3,4-Dihydro-2H-pyran 24 (9.6 g, 0.11 mol) was added over a period of 30 min to a mixture of 
p-toluenesulfonic acid (22 mg, 0.023 mmol) in diethylene glycol 23 (100 g, 0.94 mol) at 0°C. 
The reaction mixture was stirred for 2 h at 0°C. It was then allowed to warm to room 
temperature, and was stirred for 1 d. After that, the mixture was poured into 500 mL of 1 M 
NaOH (aq) and was extracted with DCM (5 × 100 mL). The combined organic layers were 
dried over MgSO4 overnight. The solvent was removed in vacuo to give compound 17 as a 
colourless oil (19 g, 69%). 1H NMR (300 MHz, CDCl3) δ 4.69 – 4.61 (m, 1H, H-5), 3.92         
– 3.41 (m, 11H, H-1, H-2, H-3, H-4, H-9 & OH), 1.91 – 1.48 (m, 6H, H-6, H-7 & H-8). 13C 
NMR (75 MHz, CDCl3) δ 99.1 (C-5), 72.5, 70.3, 66.8, 62.4, 61.6, (C-1, C-2, C-3, C-4 & C-9), 
30.5, 25.3 & 19.5 (C-6, C-7 & C-8). IR (vmax./cm-1) 3405 (OH); 2939, 2869 (-C-H); 1121, 
1064, 1032 (alkoxy -C-O) 
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4.3. Synthesis of 4,6-dichloropyrimidine 18 60 
                                                                 
4,6-Dihydroxypyrimidine 25 (25.0 g, 0.220 mol) was mixed with POCl3 (150 mL, 15 eq, 1.60 
mol) and refluxed for 3 h. After cooling to room temperature, the reaction mixture was added 
drop-wise to vigorously stirred ice water (200 mL) in an ice bath. The precipitated product 
was collected by vacuum filtration to give compound 18 as an orange solid (14.6 g). The 
filtrate was extracted with EtOAc (5 × 200 mL). The combined organic layers were dried over 
Na2SO4. The solvent was removed in vacuo to give an additional 4.82 g of compound 18, to 
give a total yield of 19.5 g, 59%. m.p. = 68 – 69°C. 1H NMR (500 MHz, DMSO-d6) δ 8.97 (s, 
1H, H-1’), 8.11 (s, 1H, H-3’). 13C NMR (75 MHz, CDCl3) δ 162.1 (C-4’ and C-2’), 158.8 (C-1’), 
121.9 (C-3’). IR (vmax./cm-1) 3072, 3040 (=C-H); 1677, 1652 (-C=N); 1585, 1429 (-C=C); 
1283 (-C-N) 
 
4.4. Synthesis of 4-chloro-6-{2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy] 
ethoxy}pyrimidine 31 
                                        
Sodium hydride (4.83 g, 0.120 mol) was flame dried under vacuum and purged with N2(g) 
three times, dry THF (150 mL) was added and the suspension was cooled to 0°C. To the 
suspension, 2-[2-((tetrahydropyranyloxy)ethoxy]ethanol 17 (19.1 g, 0.100 mol) was added 
over a period of 15 min at 0°C. The reaction was then allowed to warm to room temperature, 
and was stirred for 40 min. After that, a cold solution of 4,6-dichloropyrimidine 18 (14.9 g, 
0.100 mol) in tetrahydrofuran (150 mL) was cannulated to the reaction mixture at 0°C. The 
reaction mixture was then warmed to room temperature and stirred for 2 d. The mixture was 
partitioned between EtOAc (300 mL) and H2O (300 mL), the organic layer was collected and 
the aqueous layer was extracted with EtOAc (2 × 300 mL). The combined organic layers 
were dried over Na2SO4. The solvent was removed in vacuo  to give compound 31 as a 
colourless oil (16.4 g, 54%).1H NMR (300 MHz, CDCl3) δ 8.56 (s, 1H, H-1’), 6.83 (s, 1H,    H-
3’), 4.63 (t, J = 3 Hz, 1H, H-5), 4.60 – 4.55 (m,  2H, H-1), 3.92 – 3.82 (m, 4H, H-2, H-4 and 
H-9), 3.76 – 3.69 (m, 2H, H-3), 3.66 – 3.57 (m, 1H, H-9), 3.54 – 3.46 (m, 1H, H-4),           
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1.88 – 1.47 (m, 6H, H-6, H-7 and H-8). 13C NMR (75 MHz, CDCl3) δ 170.1 (C-2’),           
160.6 (C-4’), 158.0 (C-1’), 107.9 (C-3’), 98.8 (C-5), 70.6 (C-3), 69.0 (C-2), 66.63 (C-1), 66.60 
(C-9), 62.1 (C-4), 30.5, 25.4, 19.4 (C-6, C-7, C-8). IR (vmax./cm-1) 2942 (=C-H); 1620 (-C=N); 
1565, 1444 (Ar. –C=C); 1136 (phenyl =C-O); 1121, 1078, 1033 (alkoxy -C-O). ESI-MS (m/z) 
calculated [M+H]+ for C13H20ClN2O4 303.1103, found 303.1106. 
 
4.5. Synthesis of 2-[2-(4-chloropyrimidin-6-yloxy)ethoxy]ethanol 34 
                                                       
Concentrated HCl (4 mL) was added to a solution of 4-chloro-6-[2-(2-
(tetrahydropyranyloxy)ethoxy)ethoxy]pyrimidine 31 (7.0 g, 0.023 mol) in 2-propanol (140 
mL). The reaction mixture was stirred at room temperature overnight. After that the solvent 
was removed in vacuo and the crude material was poured into 1 M NaOH (50 mL) and was 
extracted using DCM (200 mL). The organic layer was dried over Na2SO4 and concentrated 
in vacuo  to give compound 34 as a pale yellow oil (3.2 g, 63%). 1H NMR (300 MHz, DMSO-
d6) δ 8.64 (s,1H, H-1’), 7.16 (s, 1H, H-3’), 4.50 – 4.45 (m, 2H, H-1), 3.76 – 3.71 (m, 2H, H-2), 
3.55 – 3.52 (m, 2H, H-4), 3.49 – 3.45 (m, 3H, H-3 and OH). 13C NMR (75 MHz, DMSO) δ 
169.8 (C-2’), 159.9 (C-4’), 158.3 (C-1’), 107.5 (C-3’), 72.2 (C-3), 68.1 (C-2), 66.7 (C-1), 60.0 
(C-4). IR (vmax./cm-1) 3406 (OH), 2872 (=C-H); 1565, 1444 (Ar. –C=C); 1335 (phenyl =C-O); 
1129, 1084, 1037 (alkoxy -C-O). ESI-MS (m/z) calculated [M+H]+ for C8H12ClN2O3 219.0529, 
found 219.0531. 
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4.6. General procedure for the amination to prepare compound 2-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}ethanol 16a and 
analogues 
 
a; R  = 3-bromo  
b;      = H 
c;      = 3-chloro-4-fluoro 
d;      = 3-ethynyl  
e;      = 3,5-dimethoxy 
f;       = 3,4-difluoro 
g;      = 2-chloro-4-((3-fluorobenzyl)oxy) 
h;      = 3-chloro-4-((3-fluorobenzyl)oxy) 
 
The 2-(2-((6-chloropyrimidin-4-yl)oxy)ethoxy)ethanol 34 substrate was dissolved in 2-
propanol, subsequently the desired aniline starting material 19 (1-2 eq) and catalytic amount 
of conc. HCl were added. The reaction mixture was then refluxed for 48 h. After formation of 
a new product spot, visible by TLC, the reaction was stopped. The reaction mixture was 
concentrated in vacuo and the crude material was poured into 1 M NaOH and was extracted 
using DCM. The organic layer was dried over Na2SO4 and concentrated in vacuo. The 
reaction mixture was purified by column chromatography with DCM/MeOH eluent.  
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4.6.1. Synthesis of 2-{2-[4-(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy} 
ethanol 16a 
                                       
The general procedure was followed using compound 34 (1.00 g, 4.58 mmol) and 3-
bromoaniline 19a (789 mg, 4.58 mmol, 1 eq) in 2-propanol (80 mL). The resulting mixture 
was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 16a as a light yellow solid (672 mg, 41%). m.p. = 130 – 132°C. 1H NMR (300 
MHz, DMSO-d6) δ 9.58 (s, 1H, NH), 8.42 (s, 1H, H-1’), 8.02 (t, J = 2.0 Hz, 1H, H-6’), 7.50 
(ddd, J = 8.1, 2.2, 1.1 Hz, 1H, H-8’), 7.26 (t, J = 8.1 Hz, 1H, H-9’), 7.16 (ddd, J = 7.9, 2.0, 1.0 
Hz, 1H, H-10’), 6.10 (s, 1H, H-3’), 4.61 (t, J = 5.3 Hz, 1H, OH), 4.42 – 4.35 (m, 2H, H-1), 
3.76 – 3.68 (m, 2H, H-4), 3.55 – 3.44 (m, 4H, H-2 and H-3). 13C NMR (125 MHz, DMSO) δ 
167.9 (C-2’), 161.1 (C-4’), 156.7 (C-1’), 141.0 (C-5’), 130.1 (C-9’), 124.0 (C-8’), 121.2 (C-6’), 
121.0 (C-7’), 117.7 (C-10’), 88.1 (C-3’), 71.8 (C-3), 67.9 (C-2), 64.9 (C-1), 59.6 (C-4). IR 
(vmax./cm-1) 3378 (OH); 3058 (NH); 3001 (=C-H); 2732 (-C-H); 1629 (-C=N); 1582              
(Ar. –C=C); 1253 (=C-N).  ESI-MS (m/z) calculated [M+H]+ for C14H17BrN3O3  354.0440, 
found 354.0448. 
4.6.2. Synthesis of 2-{2-[4-(phenylamino)pyrimidin-6-yloxy]ethoxy}ethanol 16b               
                                       
The general procedure was followed using compound 34 (1.39 g, 6.38 mmol) and aniline 
19b (1.19 g, 12.7 mmol, 2 eq) in 2-propanol (112 mL). The resulting mixture was purified by 
column chromatography with 94% DCM/MeOH as an eluent to yield compound 16b as a 
light yellow solid (1.27 g, 73%). m.p. = 120 – 121°C 1H NMR (300 MHz, DMSO-d6) δ 9.40 (s, 
1H, NH), 8.35 (s, 1H, H-1’), 7.57 (d, J = 7.7 Hz, 2H, H-6’), 7.31 (t, J = 7.9 Hz, 2H, H-7’), 7.01 
(t, J = 7.3 Hz, 1H, H-8’), 6.08 (s, 1H, H-3’), 4.62 (t, J = 5.0 Hz, 1H, OH), 4.40 – 4.34 (m, 2H, 
H-1), 3.76 – 3.66 (m, 2H, H-2), 3.56 – 3.44 (m, 4H, H-3 and H-4). 13C NMR (75 MHz, DMSO) 
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δ168.8 (C-2’), 161.8 (C-4’), 157.6 (C-1’), 139.5 (C-5’), 128.7 (C-7’), 122.5 (C-8’), 119.9      
(C-6’), 87.7 (C-3’), 72.1 (C-3), 68.5 (C-2), 65.2 (C-1), 60.0 (C-4). IR (vmax./cm-1) 3315 (OH); 
3246 (NH); 3081 (=C-H); 2943, 2874 (-C-H); 1608 (-C=N); 1585, 1573 (Ar. –C=C); 1252 
(=C-N). ESI-MS (m/z) calculated [M+H]+ for C14H18N3O3 276.1343, found 276.1343. 
 
4.6.3. Synthesis of 2-{2-[4-(3-chloro-4-fluorophenylamino)pyrimidin-6-yloxy] 
ethoxy}ethanol 16c                                                          
 
The general procedure was followed using compound 34 (1.94 g, 8.89 mmol) and 3-chloro-
4-fluoroaniline 19c (2.59 g, 17.8 mmol, 2 eq) in 2-propanol (150 mL). The resulting mixture 
was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 16c as a light brown solid (1.80 g, 62%). m.p. = 140 – 142°C. 1H NMR (300 MHz, 
DMSO-d6) δ 9.91 (s, 1H, NH), 8.43 (s, 1H, H-1’), 8.01 (dd, J = 6.8, 2.6 Hz, 1H, H-6’), 7.50 
(ddd, J = 9.0, 4.2, 2.7 Hz, 1H, H-10’), 7.36 (t, J = 9.1 Hz, 1H, H-9’), 6.16 (s, 1H, H-3’), 4.82 
(s, 1H, OH), 4.46 – 4.37 (m, 2H, H-1), 3.77 – 3.70 (m, 2H, H-2), 3.57 – 3.44 (m, 4H, H-3 and 
H-4). 13C NMR (75 MHz, DMSO) δ 168.3 (C-2’), 161.6 (C-4’), 157.1 (C-1’), 152.5 (d, JC-F = 
241.4 Hz, C-8’), 137.2 (d, JC-F = 2.9 Hz, C-5’), 121.0 (C-6’), 119.9 (d, JC-F = 6.7 Hz, C-10’), 
119.0 (d, JC-F = 20.0 Hz, C-7’), 116.8 (d, JC-F = 21.8 Hz, C-9’), 88.4 (C-3’), 72.3 (C-3), 68.5 
(C-2), 65.6 (C-1), 60.2 (C-4). IR (vmax./cm-1) 3430 (OH); 3040 (NH); 2732 (-C-H);              
1622 (-C=N); 1594 (Ar. –C=C); 1259 (=C-N). ESI-MS (m/z) calculated [M+H]+ for 
C14H16ClFN3O3  328.0888, found 328.0859. 
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4.6.4. Synthesis of 2-{2-[4-(3-ethynylphenylamino)pyrimidin-6-yloxy]ethoxy} 
ethanol 16d 
 
 
The general procedure was followed using compound 34 (1.00 g, 4.59 mmol) and 3-
ethynylaniline 19d (591 mg, 5.05 mmol, 1.1 eq) in 2-propanol (80 mL). The resulting mixture 
was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 16d as a yellow-orange solid (400 mg, 29%). m.p. = 145 – 147°C. 1H NMR (300 
MHz, DMSO-d6) δ 9.95 (s, 1H, NH), 8.44 (s, 1H, H-1’), 7.87 – 7.83 (m, 1H, H-6’), 7.63 – 7.56 
(m, 1H, H-10’), 7.33 (t, J = 7.9 Hz, 1H, H-9’), 7.16 – 7.10 (m, 1H, H-8’), 6.20 (s, 1H, H-3’), 
5.40 (s, 1H, OH), 4.43 – 4.36 (m, 2H, H-1), 4.18 (s, 1H, H-7), 3.78 – 3.69 (m, 2H, H-2), 3.54 
– 3.44 (m, 4H, H-3 and H-4). 13C NMR (125 MHz, DMSO) δ 167.5 (C-2’), 162.2 (C-4’), 156.1 
(C-1’), 139.6 (C-5’), 129.9 (C-9’), 127.0 (C-8’), 123.6 (C-6’), 122.5 (C-7’), 121.6 (C-10’), 88.2 
(C-3’), 83.8 (C-5), 80.9 (C-7), 72.6 (C-3), 68.7 (C-2), 67.2 (C-1), 60.5 (C-4). IR (vmax./cm-1) 
3352 (OH); 3045 (NH); 3010 (=C-H); 2874 (-C-H); 2210 (-C≡C), 1623 (-C=N);                  
1580 (Ar. –C=C); 1250 (=C-N).   ESI-MS (m/z) calculated [M+H]+ for C16H18N3O3 300.1344, 
found 300.1343. 
4.6.5. Synthesis of 2-{2-[4-(3,5-dimethoxyphenylamino)pyrimidin-6-yloxy] 
ethoxy}ethanol 16e 
 
The general procedure was followed using compound 34 (1.42 g, 6.51 mmol) and 3,4-
dimethoxyaniline 19e (1.99 g, 13.0 mmol, 2 eq) in 2-propanol (150 mL). The resulting 
mixture was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
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compound 16e as a light brown solid (468 mg, 21%). m.p. = 102 – 103°C. 1H NMR (500 
MHz, DMSO-d6) δ 9.36 (s, 1H, NH), 8.37 (s, 1H, H-1’), 6.84 (d, J = 2.3 Hz, 2H, H-6’), 6.19 (t, 
J = 2.2 Hz, 1H, H-8’), 6.09 (s, 1H, H-3’), 4.61 (t, J = 5.4 Hz, 1H, OH), 4.40 – 4.36 (m, 2H, H-
1), 3.74 (s, 6H, H-5), 3.73 – 3.71 (m, 2H, H-2), 3.54 – 3.46 (m, 4H, H-3 and H-4). 13C NMR 
(125 MHz, DMSO) δ 169.3 (C-2’), 162.4 (C-4’), 161.1 (C-7’), 158.1 (C-1’), 142.1 (C-5’), 98.6 
(C-6’), 94.6 (C-8’), 88.8 (C-3’), 72.9 (C-3), 69.1 (C-2), 65.6 (C-1), 60.7 (C-4), 55.5 (C-5). IR 
(vmax./cm-1) 3380 (OH); 3052 (NH); 2752 (-C-H); 1626 (-C=N); 1574 (Ar. –C=C);              
1253 (=C-N); 1085 (C-O).  ESI-MS (m/z) calculated [M+H]+ for C16H22N3O5  336.1547, found 
336.1554. 
4.6.6. Synthesis of 2-{2-[4-(3,4-difluorophenylamino)pyrimidin-6-yloxy]ethoxy} 
ethanol 16f 
 
The general procedure was followed using compound 34 (1.46 g, 6.69 mmol) and 3,4-
difluoroaniline 19f (1.73 g, 13.4 mmol, 2 eq) in 2-propanol (120 mL). The resulting mixture 
was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 16f as a light brown solid (1.07 g, 52%). m.p. = 135 – 136°C. 1H NMR (400 MHz, 
DMSO-d6) δ 9.68 (s, 1H, NH), 8.38 (s, 1H, H-1’), 7.85 (ddd, J = 13.5, 7.4, 2.6 Hz, 1H, H-6’), 
7.39 – 7.30 (m, 1H, H-9’), 7.29 – 7.22 (m, 1H, H-10’), 6.08 (s, 1H, H-3’), 4.39 – 4.34 (m, 2H, 
H-1), 4.11 (s, 1H, OH), 3.72 – 3.68 (m, 2H, H-2), 3.51 – 3.43 (m, 4H, H-3 and H-4). 13C NMR 
(125 MHz, DMSO) δ 167.9 (C-2’), 161.1 (C-4’), 156.6 (C-1’), 148.4 (dd, JC-F = 243.3, 13.1 
Hz, C-7’), 144.1 (dd, JC-F = 240.8, 12.9 Hz, C-8’), 136.5 (dd, JC-F = 9.2, 2.5 Hz,  C-5’), 116.8 
(d, JC-F = 17.7 Hz,  C-9’), 115.3 (dd, JC-F = 5.7, 3.0 Hz,  C-10’), 108.1 (d, JC-F = 21.4 Hz,       
C-6’), 87.8 (C-3’), 71.8 (C-4), 68.0 (C-2), 65.0 (C-1), 59.6 (C-3). IR (vmax./cm-1) 3456 (OH); 
3058 (NH); 2916 (-C-H); 1645 (-C=N); 1584 (Ar. –C=C); 1250 (=C-N). ESI-MS (m/z) 
calculated [M+H]+ for C14H16F2N3O3  312.1149, found 312.1154. 
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4.6.7. Synthesis of 2-(2-{4-[2-chloro-4-(3-fluorobenzyloxy)phenylamino] 
pyrimidin-6-yloxy}ethoxy)ethanol 16g 
 
The general procedure was followed using compound 34 (500 mg, 1.66 mmol) and 2-chloro-
4-((3-fluorobenzyl)oxy)aniline 19g (417 mg, 1.66 mmol, 1eq) in 2-propanol (50 mL). The 
resulting mixture was purified by column chromatography with 94% DCM/MeOH as an 
eluent to yield compound 16g as a cream white solid (93 mg, 13%). m.p. = 131 – 133°C. 1H 
NMR (500 MHz, DMSO-d6) δ 9.36 (s, 1H, NH), 8.35 (s, 1H, H-1’), 7.81 (d, J = 2.6 Hz, 1H,   
H-10’), 7.49 – 7.44 (m, 1H, H-16’), 7.41 – 7.37 (m, 1H, H-9’), 7.33 – 7.28 (m, 2H, H-13’ and 
H-17’), 7.21 – 7.15 (m, 2H, H-7’ and H-15’), 6.00 (s, 1H, H-3’), 5.21 (s, 2H, H-11’), 4.59 (s, 
1H, OH), 4.39 – 4.36 (m, 2H, H-1), 3.74 – 3.70 (m, 2H, H-2), 3.54 – 3.49 (m, 2H, H-4), 3.49 – 
3.46 (m, 2H, H-3). 13C NMR (125 MHz, DMSO) δ 169.3 (C-2’), 162.7 (d, JC-F = 244.4 Hz,    
C-14’), 162.4 (C-4’), 158.2 (C-1’), 149.2 (C-8’), 140.2 (d, JC-F = 7.6 Hz, C-12’), 134.7 (C-5’), 
130.9 (d, JC-F = 7.6 Hz, C-16’), 123.8 (d, JC-F = 2.5 Hz, C-17’), 122.2 (C-10’), 122.0 (C-6’), 
120.3 (C-9’), 115.4 (C-7’), 115.1 (d, JC-F = 21.4 Hz, C-15’), 114.5 (d, JC-F = 22.7 Hz, C-13’), 
88.2 (C-3’), 72.9 (C-3), 70.0 (C-11’), 69.1 (C-2), 65.6 (C-1), 60.7 (C-4). IR (vmax./cm-1) 3496 
(OH); 3303 (NH); 3115 (=C-H); 2917, 2849 (-C-H); 1623 (-C=N); 1583 (Ar. –C=C); 1352, 
1327 (phenyl -C-O); 1246 (=C-N); 1137, 1127, 1048 (alkoxy -C-O). ESI-MS (m/z) calculated 
[M+H]+ for C21H22ClFN3O4  434.1261, found 434.1277. 
4.6.8. Synthesis of 2-(2-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino] 
pyrimidin-6-yloxy}ethoxy)ethanol 16h 
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The general procedure was followed using compound 34 (500 mg, 1.66 mmol) and 3-chloro-
4-((3-fluorobenzyl)oxy)aniline 19h (417 mg, 1.66 mmol, 1 eq) in 2-propanol (50 mL). The 
resulting mixture was purified by column chromatography with 94% DCM/MeOH as an 
eluent to yield compound 16h as white solid (65 mg, 9%). m.p. = 130 – 131°C. 1H NMR (300 
MHz, DMSO-d6) δ 9.39 (s, 1H, NH), 8.35 (s, 1H, H-1’), 7.81 (d, J = 2.5 Hz, 1H, H-6’), 7.52 – 
7.41 (m, 1H, H-16’), 7.38 (dd, J = 8.9, 2.6 Hz, 1H, H-10’), 7.34 – 7.25 (m, 2H, H-13’ and H-
17’), 7.22 – 7.13 (m, 2H, H-9’ and H-15’), 5.99 (s, 1H, H-3’), 5.20 (s, 2H, H-11’), 4.62 (t, J = 
5.2 Hz, 1H, OH), 4.40 – 4.33 (m, 2H, H-1), 3.76 – 3.67 (m, 2H, H-2), 3.52 – 3.46 (m, 4H, H-3 
and H-4). 13C NMR (75 MHz, DMSO) δ 168.8 (C-2’), 162.1 (d, JC-F = 241.5 Hz, C-14’), 161.8 
(C-4’), 157.7 (C-1’), 148.7 (C-8’), 139.7 (d, JC-F = 7.5 Hz, C-12’), 134.2 (C-5’), 130.5 (d, JC-F = 
8.3 Hz, C-16’) 123.3 (d, JC-F = 3.0 Hz, C-17’), 121.7 (C-10’), 121.5 (C-6’), 119.8 (C-9’), 114.9 
(C-7’), 114.6 (d, JC-F = 21 Hz, C-15’), 114.0 (d, JC-F = 22.5 Hz, C-13’), 87.7 (C-3’), 72.3 (C-3), 
69.5 (C-11’), 68.6 (C-2), 65.1 (C-1), 60.2 (C-4). IR (vmax./cm-1) 3494 (OH); 3310 (NH); 3105 
(=C-H); 2910, 2845 (-C-H); 1615 (-C=N); 1580 (Ar. –C=C); 1350, 1325 (phenyl -C-O);      
1252 (=C-N); 1140, 1137, 1048 (alkoxy -C-O).  ESI-MS (m/z) calculated [M+H]+ for 
C21H22ClFN3O4  434.1267, found 434.1277. 
4.7. General procedure to prepare compound 2-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}acetaldehyde 15a and 
analogues 
               
 
a; R = 3-bromo  
b;    = H 
c;    = 3-chloro-4-fluoro 
d;    = 3-ethynyl  
e;    = 3,5-dimethoxy 
f;     = 3,4-difluoro 
 
IBX (2 eq.) was added to a solution of compound 16 in DMSO. The reaction mixture was 
stirred at room temperature overnight. After formation of a new product spot, visible by TLC, 
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the reaction mixture was stopped. The product was extracted using DCM and washed three 
times with water and once with brine. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo to give sticky material. The sticky material was put under high 
vacuum to give a solid, and it was confirmed to be the desired product. 
 
4.7.1. Synthesis of 2-{2-[4-(3-bromophenylamino)pyrimidin-6-yloxy]ethoxy} 
acetaldehyde 15a 
 
The general procedure was followed using compound 16a (1.19 g, 3.37 mmol) and IBX (1.88 
g, 6.73 mmol, 2 eq) in DMSO (47 mL). The desired compound 15a was yielded as an orange 
solid (1.02 g, 86%). m.p. = 52 – 53°C. 1H NMR (300 MHz, CDCl3) δ 9.74 (s, 1H, H-4), 8.34 
(s, 1H, H-1’), 7.57 – 7.48 (m, 2H, NH and H-6’), 7.31 – 7.18 (m, 3H, H-8’, H-9’ and H-10’), 
6.16 (s, 1H, H-3’), 4.57 – 4.52 (m, 2H, H-1), 4.19 (s, 2H, H-3), 3.92 – 3.87 (m, 2H, H-2). 13C 
NMR (75 MHz, CDCl3) δ 200.3 (C-4), 170.0 (C-2’), 161.9 (C-4’), 157.9 (C-1’), 139.9 (C-5’), 
130.7 (C-9’), 127.5 (C-8’), 124.9 (C-6’), 123.0 (C-7’), 120.5 (C-10’), 87.5 (C-3’), 76.7 (C-3), 
70.1 (C-2), 65.4 (C-1). IR (vmax./cm-1) 3294 (NH); 2923 (=C-H); 2895 (ald. –C-H);            
1606 (ald. –C=O); 1576 (Ar. –C=C). ESI-MS (m/z) calculated [M+H]+ for 
C14H15BrN3O3  352.0281, found 352.0291. 
4.7.2. Synthesis of 2-{2-[4-(phenylamino)pyrimidin-6-yloxy]ethoxy} 
acetaldehyde 15b                                                     
                                          
The general procedure was followed using compound 16b (610 mg, 2.22 mmol) and IBX 
(1.24 g, 4.44 mmol, 2 eq) in DMSO (15 mL). The desired compound 15b was yielded as a 
dark brown solid (400 mg, 66%). m.p. = 59 – 61°C. 1H NMR (500 MHz, CDCl3) δ 9.73 (s, 
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1H, H-4), 8.32 (s, 1H, H-1’), 7.43 (s, 1H, NH), 7.40 – 7.35 (m, 2H, H-6’), 7.30 – 7.27 (m, 2H, 
H-7’), 7.20 – 7.14 (m, 1H, H-8’), 6.16 (s, 1H, H-3’), 4.57 – 4.47 (m, 2H, H-1), 4.16 (s, 2H,    
H-3), 3.93 – 3.83 (m, 2H, H-2). 13C NMR (125 MHz, CDCl3) δ 200.4 (C-4), 169.9 (C-2’), 
162.5 (C-4’), 157.8 (C-1’), 138.2 (C-5’), 129.5 (C-7’), 124.9 (C-8’), 122.6 (C-6’), 86.7 (C-3’), 
76.6 (C-3), 70.1 (C-2), 65.2 (C-1). IR (vmax./cm-1) 3242 (NH), 2922 (=C-H); 2854 (ald. –C-H); 
1608 (ald. –C=O); 1581 (Ar. –C=C). ESI-MS (m/z) calculated [M+H]+ for 
C14H16N3O3  274.1182, found 274.1186. 
 
4.7.3. Synthesis of 2-{2-[4-(3-chloro-4-fluorophenylamino)pyrimidin-6-yloxy] 
ethoxy}acetaldehyde 15c 
 
The general procedure was followed using compound 16c (800 mg, 2.45 mmol) and IBX 
(1.37 g, 4.89 mmol, 2 eq) in DMSO (25 mL). The desired compound 15c was yielded as a 
dark brown solid (683 mg, 86%). m.p. = 67 – 69°C. 1H NMR (500 MHz, CDCl3) δ 9.72 (s, 1H, 
H-4), 8.29 (s, 1H, H-1’), 7.78 (s, 1H, NH), 7.44 – 7.37 (m, 1H, H-6’), 7.19 – 7.05 (m, 2H, H-9’ 
and H-10’), 6.04 (s, 1H, H-3’), 4.56 – 4.52 (m, 2H, H-1), 4.18 (s, 2H, H-3), 3.91 – 3.86 (m, 
2H, H-2). 13C NMR (125 MHz, CDCl3) δ 200.3 (C-4), 170.0 (C-2’), 162.3 (C-4’), 157.7 (C-1’), 
155.3 (d, JC-F = 252.0 Hz, C-8’), 135.0 (d, JC-F = 3.8 Hz, C-5’), 124.9 (C-6’), 122.6 (d, JC-F = 
6.3 Hz, C-10’), 121.6 (d, JC-F = 18.9 Hz, C-7’), 117.2 (d, JC-F = 22.7 Hz, C-9’), 87.1 (C-3’), 
76.7 (C-3), 70.1 (C-2), 65.4 (C-1). IR (vmax./cm-1) 3064 (NH); 2923 (=C-H); 2853 (ald. –C-H);                     
1702 (ald. –C=O); 1585 (Ar. –C=C). ESI-MS (m/z) calculated [M+H]+ for 
C14H14ClFN3O3  326.0705, found 326.0702. 
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4.7.4. Synthesis of 2-{2-[4-(3-ethynylphenylamino)pyrimidin-6-yloxy]ethoxy} 
acetaldehyde 15d 
 
The general procedure was followed using compound 16d (563 mg, 1.88 mmol) and IBX 
(1.05 g, 3.77 mmol, 2 eq) in DMSO (22 mL). The desired compound 15d was yielded as a 
dark brown solid (349 mg, 62%). m.p. = 67 – 68°C. 1H NMR (500 MHz, CDCl3) δ 9.73 (s, 
1H, H-4), 8.34 (s, 1H, H-1’), 7.46 – 7.39 (m, 2H, NH and H-6’), 7.34 – 7.27 (m, 3H, H-8’, H-9’ 
and H-10’), 6.15 (s, 1H, H-3’), 4.56 – 4.53 (m, 2H, H-1), 4.18 (s, 2H, H-3), 3.91 – 3.87 (m, 
2H, H-2), 3.11 (s, 1H, H-7). 13C NMR (125 MHz, CDCl3) δ 200.3 (C-4), 169.5 (C-2’), 162.2 
(C-4’), 157.7 (C-1’), 139.5 (C-5’), 129.1 (C-9’), 127.1 (C-8’), 124.5 (C-6’), 122.8 (C-7’), 121.8 
(C-10’), 88.0 (C-3’), 83.3 (C-5),77.6 (C-7), 76.6 (C-3), 70.1 (C-2), 65.1(C-1). IR (vmax./cm-1) 
3292 (NH); 2920 (=C-H); 2895 (ald. –C-H); 1610 (ald. –C=O); 1574 (Ar. –C=C). ESI-MS 
(m/z) calculated [M+H]+ for C16H16N3O3  298.1184, found 298.1186. 
4.7.5. Synthesis of 2-{2-[4-(3,5-dimethoxyphenylamino)pyrimidin-6-yloxy] 
ethoxy}acetaldehyde 15e 
 
The general procedure was followed using compound 16e (290 mg, 0.87 mmol) and IBX 
(484 mg, 1.73 mmol, 2 eq) in DMSO (12 mL). The desired compound 15e was yielded as a 
dark brown solid (177 mg, 61%). m.p. = 56 – 58°C. 1H NMR (300 MHz, CDCl3) δ 9.73 (s, 1H, 
H-4), 8.33 (s, 1H, H-1’), 7.17 (s, 1H, NH), 6.44 (d, J = 2.2 Hz, 2H, H-6’), 6.27 (t, J = 2.2 Hz, 
1H, H-8’), 6.23 (s, 1H,  H-3’), 4.56 – 4.50 (m, 2H, H-1), 4.18 (s, 2H,  H-3), 3.92 – 3.86 (m, 
2H, H-2), 3.79 (s, 6H, H-5). 13C NMR (125 MHz, CDCl3) δ 200.7 (C-4), 170.0 (C-2’), 162.6 
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(C-4’), 161.3 (C-7’), 157.7 (C-1’), 140.0 (C-5’), 100.8 (C-6’), 96.7 (C-8’), 87.4 (C-3’), 76.7    
(C-3), 70.2 (C-2), 65.3 (C-1), 55.4 (C-5). IR (vmax./cm-1) 3068 (NH); 2922 (=C-H);                  
2895 (ald. –C-H); 1695 (ald. –C=O); 1576 (Ar. –C=C). ESI-MS (m/z) calculated [M+H]+ for 
C16H20N3O5  334.1393, found 334.1397. 
4.7.6. Synthesis of 2-{2-[4-(3,4-difluorophenylamino)pyrimidin-6-yloxy]ethoxy} 
acetaldehyde 15f 
 
The general procedure was followed using compound 16f (440 mg, 1.41 mmol) and IBX 
(792 mg, 28.3 mmol, 2 eq) in DMSO (18 mL). The desired compound 15f was yielded as a 
dark brown solid (396 mg, 90%). m.p. = 51 – 52°C. 1H NMR (500 MHz, CDCl3) δ 9.73 (s, 1H, 
H-4), 8.34 (s, 1H, H-1’), 7.28 – 7.22 (m, 1H, H-6’), 7.20 – 7.10 (m, 1H, H-9’), 7.03 – 6.93 (m, 
2H, H-10 and NH), 6.06 (s, 1H, H-3’), 4.58 – 4.51 (m, 2H, H-1), 4.18 (s, 2H, H-3), 3.92 – 3.87 
(m, 2H, H-2). 13C NMR (125 MHz, CDCl3) δ 200.3 (C-4), 170.0 (C-2’), 162.1 (C-4’), 158.0   
(C-1’), 150.5 (dd, JC-F = 249.5, 13.9 Hz, C-7’), 147.5 (dd, JC-F = 247.0, 12.6 Hz, C-8’), 134.8 
(dd, JC-F = 11.3, 6.3 Hz, C-5’), 118.4 (dd, JC-F = 6.3, 3.8 Hz, C-10’), 117.8 (dd, JC-F = 18.1, 1.3 
Hz, C-9’), 112.0 (d, JC-F = 19.7 Hz, C-6’), 87.3 (C-3’), 76.7 (C-3), 70.2 (C-2), 65.4 (C-1).             
IR (vmax./cm-1) 3062 (NH); 2890 (=C-H); 2801 (ald. –C-H); 1695 (ald. –C=O);                   
1595 (Ar. –C=C). ESI-MS (m/z) calculated [M+H]+ for C14H14F2N3O3  310.0994, found 
310.0998. 
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4.8. General procedure to prepare 2-hydroxy-N-isopropyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}propanamide 14a and 
analogues 
 
 
a; R = 3-bromo  
b;    = H 
c;    = 3-chloro-4-fluoro 
d;    = 3-ethynyl  
e;    = 3,5-dimethoxy 
f;     = 3,4-difluoro 
 
Compound 15 was dissolved in DCM and diluted with EtOAc. AcOH and isopropyl 
isocyanide were then consecutively added. The reaction mixture was stirred at room 
temperature for 24 h, after that the mixture was concentrated in vacuo. K2CO3 in MeOH/H2O 
was then added to the concentrate and it was stirred at room temperature for 3 h. The 
mixture was extracted with DCM and washed with H2O, the organic layer was collected and 
the aqueous layer was back-extracted with DCM (× 2). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The reaction mixture was purified by column 
chromatography with 94% DCM/MeOH as an eluent to give the desired product. 
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4.8.1. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3-bromophenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 14a 
 
The general procedure was followed using compound 15a (200 mg, 0.568 mmol) in DCM (7 
mL) and EtOAc (14 mL). Isopropyl isocyanide (39 mg, 0.568 mmol), AcOH and K2CO3 (173 
mg, 1.25 mmol) in MeOH (29 mL) and H2O (15 mL) were added. The resulting mixture was 
purified by column chromatography with 94% DCM/MeOH as an eluent to yield compound 
14a as a pale yellow solid (147 mg, 59%). m.p. = 103 – 105°C. 1H NMR (500 MHz, CDCl3) δ 
8.31 (s, 1H, H-1’), 7.87 (s, 1H, NH), 7.50 (s, 1H, H-6’), 7.29 – 7.18 (m, 3H, H-8’, H-9’ and     
H-10’), 6.68 (d, J = 7.8 Hz, 1H, NH), 6.08 (s, 1H, H-3’), 4.52 – 4.41 (m, 2H, H-1), 4.22 (t, J = 
5.5 Hz, 1H, H-4), 4.11 – 4.02 (m, 1H, H-6), 3.87 – 3.77 (m, 3H, H-2 and H-3), 3.73 (dd, J = 
9.6, 6.5 Hz, 1H, H-3), 1.15 (d, J = 6.7 Hz, 3H, H-7), 1.13 (d, J = 6.7 Hz, 3H, H-7). 13C NMR 
(125 MHz, CDCl3) δ 170.6 (C-5), 170.0 (C-2’), 161.9 (C-4’), 157.9 (C-1’), 140.0 (C-5’), 130.7 
(C-9’), 127.4 (C-8’), 124.8 (C-6’), 122.9 (C-7’), 120.4 (C-10’), 87.4 (C-3’), 72.7 (C-3), 70.3 
(C-4), 69.7 (C-2), 65.4 (C-1), 41.2 (C-6), 22.7 (C-7). IR (vmax./cm-1) 3298 (OH); 2925 (NH); 
1648 (–C=O); 1575 (Ar. –C=C); 1265, 1296 (alkoxy –C-O); 1049 (alcohol –C-O).ESI-MS 
(m/z) calculated [M+H]+ for C18H24BrN4O4  439.0963, found 439.0975.  
4.8.2. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(phenylamino)pyrimidin-6-
yloxy]ethoxy}propanamide 14b 
                         
The general procedure was followed using compound 15b (367 mg, 1.34 mmol) in DCM (14 
mL) and EtOAc (28 mL). Isopropyl isocyanide (186 mg, 2.69 mmol), AcOH and K2CO3 (408 
mg, 2.95 mmol) in MeOH (54 mL) and H2O (27 mL) were added. Compound 14b was 
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yielded as a brown solid (175 mg, 36%). m.p. = 104 – 105°C. 1H NMR (500 MHz, CDCl3) δ 
8.30 (s, 1H, H-1’), 7.50 (s, 1H, NH), 7.39 – 7.33 (m, 2H, H-6’), 7.29 – 7.26 (m, 2H, H-7’), 7.19 
– 7.14 (m, 1H, H-8’), 6.63 (s, 1H, NH), 6.09 (s, 1H, H-3’), 4.49 – 4.41 (m, 2H, H-1), 4.19 (t, J 
= 5.7 Hz, 1H, H-4), 4.11 – 4.00 (m, 1H, H-6), 3.83 – 3.77 (m, 3H, H-2 and H-3), 3.73 – 3.69 
(m, 1H, H-2), 1.14 (d, J = 6.6 Hz, 3H, H-7), 1.12 (d, J = 6.6 Hz, 3H, H-7). 13C NMR (125 
MHz, CDCl3) δ 170.5 (C-5), 169.9 (C-2’), 162.5 (C-4’), 157.9 (C-1’), 138.2 (C-5’), 129.5 
(C-7’), 124.9 (C-8’), 122.5 (C-6’), 86.6 (C-3’),  72.6 (C-3), 70.1 (C-4), 69.7 (C-2), 65.2 (C-1), 
41.1 (C-6), 22.6 (C-7). IR (vmax./cm-1) 3249 (OH); 3086 (NH); 2974 (=C-H); 1610 (–C=O); 
1587 (Ar. –C=C), 1253 ((=C-N).  ESI-MS (m/z) calculated [M+H]+ for C18H25N4O4  361.1867, 
found 361.1870. 
4.8.3. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3-chloro-4-fluorophenyl 
amino)pyrimidin-6-yloxy]ethoxy}propanamide 14c 
 
The general procedure was followed using compound 15c (210 mg, 0.646 mmol) in DCM (9 
mL) and EtOAc (16 mL). Isopropyl isocyanide (49 mg, 0.710 mmol), AcOH and K2CO3 (250 
mg, 1.81 mmol) in MeOH (33 mL) and H2O (17 mL) were added. The resulting mixture was 
purified by column chromatography with 94% DCM/MeOH as an eluent to yield compound 
14c as a light brown solid (160 mg, 60%). m.p. = 110 – 112°C. 1H NMR (500 MHz, CDCl3) δ 
8.33 (s, 1H, H-1’), 7.42 (dd, J = 6.3, 2.1 Hz, 1H, H-6’), 7.19 – 7.09 (m, 3H, NH, H-9’ and H-
10’), 6.59 (d, J = 7.4 Hz, 1H, NH), 5.98 (s, 1H, H-3’), 4.53 – 4.44 (m, 2H, H-1), 4.18 (t, J = 
5.7 Hz, 1H, H-4), 4.12 – 4.02 (m, 1H, H-6), 3.83 (t, J = 4.4 Hz, 2H, H-2), 3.79 (dd, J = 9.8, 
5.1 Hz, 1H, H-3), 3.72 (dd, J = 9.7, 6.4 Hz, 1H, H-3), 1.16 (d, J = 6.6 Hz, 3H, H-7), 1.14      
(d, J = 6.6 Hz, 3H, H-7). 13C NMR (125 MHz, CDCl3) δ 170.4 (C-5), 170.0 (C-2’), 162.3 
(C-4’), 158.0 (C-1’), 155.3 (d, JC-F = 247.4 Hz, C-8’), 135.0 (d, JC-F = 3.4 Hz, C-5’), 124.9 
(C-6’), 122.5 (d, JC-F = 6.9 Hz,  C-10’), 121.7 (d, JC-F = 18.9 Hz, C-7’), 117.2 (d, JC-F = 22.2 
Hz, C-9’), 87.2 (C-3’), 72.5 (C-3), 70.2 (C-4), 69.7 (C-2), 65.4 (C-1), 41.2 (C-6), 22.6 (C-7). 
IR (vmax./cm-1) 3304 (OH); 2973 (NH); 1612 (–C=O); 1584 (Ar. –C=C); 1249, 1298            
(alkoxy –C-O); 1052 (alcohol –C-O). ESI-MS (m/z) calculated [M+H]+ for 
C18H23ClFN4O4  413.1378, found 413.1386. 
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4.8.4. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3-ethynylphenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 14d 
 
The general procedure was followed using compound 15d (339 mg, 1.14 mmol) in DCM (14 
mL) and EtOAc (28 mL). Isopropyl isocyanide (79 mg, 1.14 mmol, 1 eq.), AcOH and K2CO3 
(424 mg, 3.07 mmol) in MeOH (57 mL) and H2O (29 mL) were added. The resulting mixture 
was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 14d as a cream white solid (170 mg, 39%). m.p. =107 – 108°C. 1H NMR (500 
MHz, CDCl3) δ 8.30 (s, 1H, H-1’), 7.71 (s, 1H, NH), 7.42 (s, 1H, H-6’), 7.33 – 7.25 (m, 3H,   
H-8’, H-9’ and H-10’), 6.66 (d, J = 7.9 Hz, 1H, NH), 6.07 (s, 1H, H-3’), 4.49 – 4.41 (m, 2H,   
H-1), 4.23 – 4.13 (m, 2H, H-4 and OH), 4.10 – 4.03 (m, 1H, H-6), 3.84 – 3.79 (m, 3H, H-2 
and  H-3), 3.77 – 3.69 (m, 1H, H-3), 3.11 (s, 1H, H-9), 1.15 (d, J = 6.6 Hz, 3H, H-7), 1.13 (d, 
J = 6.6 Hz, 3H, H-7). 13C NMR (125 MHz, CDCl3) δ 170.5 (C-5), 170.0 (C-2’), 162.2 (C-4’), 
157.9 (C-1’), 138.6 (C-5’), 129.5 (C-9’), 128.3 (C-8’), 125.5 (C-6’), 123.4 (C-7’), 122.7 
(C-10’), 87.1 (C-3’), 83.0 (C-8), 78.0 (C-9), 72.7 (C-3), 70.3 (C-4), 69.7 (C-2), 65.3 (C-1), 
41.2 (C-6), 22.7 (C-7). IR (vmax./cm-1) 3286 (OH); 2926 (NH); 1646 (–C=O); 1587 (Ar. –C=C); 
1253 (alkoxy –C-O); 1050 (alcohol –C-O). ESI-MS (m/z) calculated [M+H]+ for C20H25N4O4 
385.1863, found 385.1870. 
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4.8.5. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3,5-dimethoxyphenyl 
amino)pyrimidin-6-yloxy]ethoxy}propanamide 14e 
 
The general procedure was followed using compound 15e (147 mg, 0.441 mmol) in DCM (6 
mL) and EtOAc (12 mL). Isopropyl isocyanide (30.5 mg, 0.710 mmol, 1 eq.), AcOH and 
K2CO3 (163 mg, 1.18 mmol) in MeOH (22 mL) and H2O (11 mL) were added. The resulting 
mixture was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound  14e as a brown solid (69 mg, 37%). m.p. = 98 – 99°C. 1H NMR (500 MHz, 
CDCl3) δ 8.31 (s, 1H, H-1’), 7.14 (s, 1H, NH), 6.60 (d, J = 7.1 Hz, 1H, NH), 6.43 (d, J = 2.1 
Hz, 2H, H-6’), 6.27 (t, J = 2.0 Hz, 1H, H-8’), 6.18 (s, 1H, H-3’), 4.51 – 4.43 (m, 2H, H-1), 4.18 
(t, J = 5.7 Hz, 1H, H-4), 4.11 – 4.03 (m, 1H, H-6), 3.83 (t, J = 4.5 Hz, 2H, H-2), 3.79 (s, 6H, 
H-8), 3.72 (dd, J = 9.7, 6.3 Hz, 2H, H-3), 1.74 (s, 1H, OH), 1.15 (d, J = 6.6 Hz, 3H, H-7), 1.13 
(d, J = 6.6 Hz, 3H, H-7). 13C NMR (125 MHz, CDCl3) δ 170.4 (C-5), 170.0 (C-2’), 162.3 
(C-4’), 161.5 (C-7’), 157.9(C-1’), 139.9 (C-5’), 100.8 (C-6’), 96.6 (C-8’), 87.3 (C-3’), 72.5 
(C-3), 70.1 (C-4), 69.7 (C-2), 65.2 (C-1), 55.4 (C-8), 41.2 (C-6), 22.6 (C-7). IR (vmax./cm-1) 
3249 (OH); 2935 (NH); 1609 (–C=O); 1584 (Ar. –C=C); 1254 (alkoxy –C-O); 1056      
(alcohol –C-O). ESI-MS (m/z) calculated [M+H]+ for C20H29N4O6 421.2075, found 421.2082. 
4.8.6. Synthesis of 2-hydroxy-N-isopropyl-3-{2-[4-(3,4-difluorophenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 14f 
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The general procedure was followed using compound 15f (396 mg, 1.28 mmol) in DCM (15 
mL) and EtOAc (30 mL). Isopropyl isocyanide (88.4 mg, 1.28 mmol, 1 eq.), AcOH and 
K2CO3 (440 mg, 3.18 mmol) in MeOH (58 mL) and H2O (29 mL) were added. The resulting 
mixture was purified by column chromatography with 94% DCM/MeOH as an eluent to yield 
compound 14f as a cream white solid (179 mg, 34%). m.p. =122 – 123°C. 1H NMR (500 
MHz, CDCl3) δ 8.30 (s, 1H, H-1’), 7.67 (s, 1H, NH), 7.29 – 7.22 (m, 1H, H-6’), 7.14 (q, J = 9.1 
Hz, 1H, H-9’), 7.02 – 6.97 (m, 1H, H-10’), 6.66 (d, J = 7.7 Hz, 1H, NH), 5.99 (s, 1H, H-3’), 
4.50 – 4.42 (m, 2H, H-1), 4.21 (t, J = 5.3 Hz, 1H, H-4), 4.12 – 4.03 (m, 2H, H-6 and OH), 
3.85 – 3.79 (m, 3H, H-2 and H-3), 3.75 – 3.70 (m, 1H, H-3), 1.15 (d, J = 6.8 Hz, 3H, H-7), 
1.13 (d, J = 6.7 Hz, 3H, H-7). 13C NMR (125 MHz, CDCl3) δ 170.5 (C-5), 169.9 (C-2’), 162.2 
(C-4’), 157.9 (C-1’), 150.4 (dd, JC-F = 239.4, 13.5 Hz, C-7’), 147.4 (dd, JC-F = 252.0, 12.7 Hz, 
C-8’), 135.1 (dd, JC-F = 8.2, 3.3 Hz, C-5’), 118.2 (dd, JC-F = 5.9, 3.4 Hz, C-10’), 117.7 (dd,               
JC-F = 18.1, 0.8 Hz, C-9’), 111.8 (d, JC-F = 19.7 Hz, C-6’), 87.2 (C-3’), 72.7 (C-3), 70.4 (C-4), 
69.7 (C-2), 65.4 (C-1), 41.2 (C-6), 22.7 (C-7). IR (vmax./cm-1) 3304 (OH); 2984 (NH); 1610    
(–C=O); 1582 (Ar. –C=C); 1253 (alkoxy –C-O); 1053 (alcohol –C-O). ESI-MS (m/z) 
calculated [M+H]+ for C18H23F2N4O4 397.1676, found 397.1682. 
4.9. General procedure to prepare 2-oxo-N-isopropyl-3-{2-[4-(phenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 13a and analogues 
  
a; R = 3-bromo  
b;    = H 
c;    = 3-chloro-4-fluoro 
d;    = 3-ethynyl  
e;    = 3,5-dimethoxy 
f;     = 3,4-difluoro 
 
IBX (2 eq.) was added to a solution of compound 14 in dry DMSO. The reaction mixture was 
stirred at room temperature overnight. After formation of a new product spot, visible by TLC, 
the reaction mixture was stopped. The product was extracted using DCM and washed three 
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times with H2O and once with brine. The combined organic layers were dried over Na2SO4 
and concentrated in vacuo to give sticky material. The sticky material was put under high 
vacuum to give a solid, and it was confirmed to be the desired product. 
 
4.9.1. Synthesis of 2-oxo-N-isopropyl-3-{2-[4-(phenylamino)pyrimidin-6-yloxy] 
ethoxy}propanamide 13b   
                                          
The general procedure was followed using compound 14b (47 mg, 0.13 mmol) and IBX (73 
mg, 0.261 mmol, 2 eq) in DMSO (2 mL). The desired compound 13b was yielded as a pale 
yellow solid (33 mg, 70%). m.p. = 50 – 51°C. 1H NMR (300 MHz, CDCl3) δ 8.32 (s, 1H,       
H-1’), 7.43 (s, 1H, NH), 7.41 – 7.33 (m, 2H, H-6’), 7.30 – 7.26 (m, 2H, H-7’), 7.20 – 7.12 (m, 
1H, H-8’), 6.75 (s, 1H, NH), 6.17 (s, 1H, H-3’), 4.90 (s, 2H, H-3), 4.58 – 4.44 (m, 2H, H-1), 
4.11 – 3.95 (m, 1H, H-6), 3.93 – 3.81 (m, 2H, H-2), 1.20 (d, J = 6.6 Hz, 6H, H-7). 13C NMR 
(75 MHz, CDCl3) δ 194.7 (C-4), 169.9 (C-2’), 162.4 (C-4’) , 158.3 (C-5), 157.8 (C-1’) , 138.2 
(C-5’), 129.5 (C-7’), 124.8 (C-8’), 122.5 (C-6’), 86.8 (C-3’), 73.4 (C-3), 69.9 (C-2), 65.3 (C-1), 
41.5 (C-6), 22.3 (C-7). IR (vmax./cm-1) 3299 (NH); 2925 (=C-H); 1723 (ketone –C=O); 1649 
(amide –C=O); 1249 (alkoxy =C-O). ESI-MS (m/z) calculated [M+H]+ for 
C18H23N4O4  359.1709, found 359.1714. 
4.9.2. Synthesis of 2-oxo-N-isopropyl-3-{2-[4-(3-chloro-4-fluorophenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 13c 
 
The general procedure was followed using compound 14c (120 mg, 0.29 mmol) and IBX 
(163 mg, 0.58 mmol, 2 eq) in DMSO (4 mL). The desired compound 13c was yielded as a 
pale yellow solid (100 mg, 84%). m.p. = 72 – 73°C. 1H NMR (300 MHz, CDCl3) δ 8.27 (s, 1H, 
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H-1’), 7.90 (s, 1H, NH), 7.40 (dd, J = 6.4, 2.5 Hz, 1H, H-6’), 7.20 – 7.13 (m, 1H, H-10’), 7.13 
– 7.06 (m, 1H, H-9’), 6.77 (d, J = 7.8 Hz, 1H, NH), 6.02 (s, 1H, H-3’), 4.88 (s, 2H, H-3), 4.53 
– 4.46 (m, 2H, H-1), 4.09 – 3.95 (m, 1H, H-6), 3.88 – 3.82 (m, 2H, H-2), 1.18 (d, J = 6.6 Hz, 
6H, H-7). 13C NMR (125 MHz, CDCl3) δ 194.7 (C-4), 169.8 (C-2’), 162.2 (C-4’), 158.4 (C-5), 
157.5 (C-1’) 156.3 (C-8’), 135.0 (C-5’), 124.8 (C-6’), 122.5 (C-10’), 121.7 (C-7’), 117.2 (C-9’), 
87.3 (C-3’), 73.4 (C-3), 69.9 (C-2), 65.5 (C-1), 41.6 (C-6), 22.3 (C-7). IR (vmax./cm-1) 3294 
(NH); 2921 (=C-H); 1646 (amide –C=O); 1259 ( =C-N); 1612 (ketone –C=O). ESI-MS (m/z) 
calculated [M+H]+ for C18H21ClFN4O4  411.1222, found 411.1230. 
 
4.9.3. Synthesis of 2-oxo-N-isopropyl-3-{2-[4-(3-ethynylphenylamino)pyrimidin-
6-yloxy]ethoxy}propanamide 13d 
 
The general procedure was followed using compound 14d (52 mg, 0.135 mmol) and IBX (76 
mg, 0.271 mmol, 2 eq) in DMSO (2 mL). The desired compound 13d was yielded as a dark 
brown solid (39 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H, H-1’), 7.68 (s, 1H, NH), 
7.43 (s, 1H, H-6’), 7.30 (m, 3H, H-8’, H-9’ and H-10’), 6.77 (d, J = 7.1 Hz, 1H, NH), 6.15 (s, 
1H, H-3’), 4.90 (s, 2H, H-3), 4.56 – 4.50 (m, 2H, H-1), 4.11 – 3.99 (m, 1H, H-6), 3.91 – 3.86 
(m, 2H, H-2), 3.11 (s, 1H, H-9), 1.20 (d, J = 6.6 Hz, 6H, H-7). 13C NMR (125 MHz, CDCl3) δ 
194.7 (C-4), 170.0 (C-2’), 162.1 (C-4’), 158.4 (C-5), 157.8 (C-1’), 138.6 (C-5’), 129.5 (C-9’), 
128.3 (C-8’), 125.5 (C-6’), 123.4 (C-7’), 122.7 (C-10’), 87.3 (C-3’), 83.0 (C-8), 78.0 (C-9), 
73.6 (C-3), 69.9 (C-2), 65.4 (C-1), 41.6 (C-6), 22.3 (C-7). IR (vmax./cm-1) 3298 (NH); 2923 
(=C-H); 1646 (ketone –C=O); 1612 (amide –C=O); 1259 (=C-N). ESI-MS (m/z) calculated 
[M+H]+ for C20H23N4O4 383.1700, found 383.1714. 
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4.9.4. Synthesis of 2-oxo-N-isopropyl-3-{2-[4-(3,5-dimethoxyphenylamino) 
pyrimidin-6-yloxy]ethoxy}propanamide 13e 
 
 
The general procedure was followed using compound 14e and IBX in DMSO (2 mL). The 
desired compound 13e was yielded as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.32 
(s, 1H, H-1’), 7.34 (s, 1H, NH), 6.74 (d, J = 8.3 Hz, 1H, NH), 6.47 – 6.43 (m, 2H, H-6’),      
6.29 – 6.26 (m, 1H, H-8’), 6.24 – 6.22 (m, 1H, H-3’), 4.90 (s, 2H, H-3), 4.56 – 4.50 (m, 2H,   
H-1), 4.09 – 4.00 (m, 1H, H-6), 3.94 – 3.84 (m, 2H, H-2), 3.79 (s, 6H, H-8), 1.20 (d, J = 6.6 
Hz, 6H, H-7). 13C NMR (125 MHz, CDCl3) δ 194.7 (C-4), 170.1 (C-2), 161.5 (C-4’), 160.7   
(C-7’), 158.4 (C-5), 157.5 (C-1’), 139.8 (C-5’), 100.8 (C-6’), 96.8 (C-8’), 87.4 (C-3’), 73.4     
(C-3), 69.9 (C-2), 65.4 (C-1), 55.4 (C-8), 41.6 (C-6), 22.4 (C-7). IR (vmax./cm-1) 3358 (NH); 
2974 (=C-H); 1721 ( ketone –C=O); 1649 (amide –C=O); 1249 (=C-N). ESI-MS (m/z) 
calculated [M+H]+ for C20H27N4O6 419.1907, found 419.1925. 
4.10. General procedure to prepare 2-hydroxy-3-{2-[4-(3-bromophenylamino) 
pyrimidin-6-yloxy]ethoxy}propanenitriles 22a and 22b 
 
a; R = 3-bromo  
b;    = H 
To a round bottomed flask was added a solution of NaHSO3 in water, the flask was then 
cooled in an ice bath. A solution of compound 15 in MeOH was then added and the reaction 
mixture was stirred in an ice bath for 2 h. After that a solution of KCN in water was added 
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and the reaction was left to stir at room temperature overnight. The mixture was extracted 
with DCM and washed with H2O and the organic layer was collected and dried over Na2SO4 
and concentrated in vacuo. The reaction mixture was purified by preparative thin layer 
chromatography with 97% DCM/MeOH as an eluent to give the desired product. 
 
4.10.1. Synthesis of 2-hydroxy-3-{2-[4-(3-bromophenylamino)pyrimidin-6-
yloxy]ethoxy}propanenitrile 22a 
 
The general procedure was followed using NaHSO3 (64.9 mg, 0.63 mmol, 1.1 eq.) in H2O (2 
mL), compound 15a (200 mg, 0.57 mmol, 1 eq.) in MeOH (3 mL) and KCN (40.1 mg, 0.63 
mmol, 1.1 eq.) in H2O (2 mL). Compound 22a was yielded as a pale yellow sticky solid (41.2 
mg, 19%).1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H, H-1’), 7.49 (s, 1H, H-6’), 7.29 – 7.27 (m, 
1H, NH), 7.25 – 7.17 (m, 3H, H-8’, H-9’ and H-10’), 6.07 (s, 1H, H-3’), 4.69 (s, 1H, OH), 4.60 
(t, J = 4.2 Hz, 1H, H-4), 4.52 – 4.47 (m, 2H, H-1), 3.99 – 3.86 (m, 2H, H-2), 3.84 – 3.79 (m, 
2H, H-3). 13C NMR (125 MHz, CDCl3) δ 169.9 (C-2’), 161.9 (C-4’), 157.9 (C-1’), 139.7 (C-5’), 
130.7 (C-9’), 127.7 (C-8’), 125.0 (C-6’), 123.0 (C-7’), 120.6 (C-10’), 118.2 (C-5), 87.5 (C-3’), 
72.4 (C-3), 70.5 (C-2), 65.4 (C-1), 60.8 (C-4). IR (vmax./cm-1) 3105 (OH); 3058 (NH);            
2984 (-C-H); 2215 (-C≡N); 1296 (alkoxy –C-O). ESI-MS (m/z) calculated [M+H]+ for 
C15H16BrN4O3 379.0390, found 379.0400. 
 
4.10.2. Synthesis of 2-hydroxy-3-{2-[4-(phenylamino)pyrimidin-6-yloxy] 
ethoxy}propanenitrile 22b 
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The general procedure was followed using NaHSO3 (209 mg, 2.01 mmol, 1.1 eq.) in H2O (2 
mL), compound 15b (500 mg, 1.83 mmol, 1 eq.) in MeOH (3 mL) and KCN (131 mg, 2.01 
mmol, 1.1 eq.) in H2O (2 mL). Compound 22b was yielded as a pale yellow sticky solid (131 
mg, 24%). 1H NMR (500 MHz, CDCl3) δ 8.28 (s, 1H, H-1’), 7.51 (s, 1H, NH), 7.35 (t, J = 7.6 
Hz, 2H, H-6’), 7.25 – 7.23 (m, 2H, H-7’), 7.15 (t, J = 7.4 Hz, 1H, H-8’), 6.07 (s, 1H, H-3’), 
4.60 (t, J = 4.3 Hz, 1H, H-4), 4.45 (t, J = 4.4 Hz, 2H, H-1), 3.95 – 3.83 (m, 3H, H-2 and OH), 
3.80 (d, J = 4.2 Hz, 2H, H-3). 13C NMR (125 MHz, CDCl3) δ 169.9 (C-2’), 162.5 (C-4’), 157.8 
(C-1’), 138.1 (C-5’), 129.5 (C-7’), 125.0 (C-8’), 122.6 (C-6’), 118.4 (C-5’), 86.6 (C-3’), 72.5 
(C-3), 70.4 (C-2), 65.3 (C-1), 60.7 (C-4). IR (vmax./cm-1) 3250 (OH); 3086 (NH); 2989 (-C-H); 
2220 (-C≡N); 1252 (alkoxy –C-O). ESI-MS (m/z) calculated [M+H]+ for C15H17N4O3 301.1295, 
found 301.1295. 
 
4.11. General procedure for the attempted preparation of methyl-3-{2-[4-(3-
bromophenylamino)pyrimidin-6-yloxy]ethoxy}-2-hydroxypropanoate 21 
which yielded methyl N-3-bromophenyl-6-[2-(2,2-dimethoxyethoxy) 
ethoxy]pyrimidin-4-amine 41a and 41b 
 
 
a; R = 3-bromo  
b;    = H 
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To a round bottomed flask was added 98% sulfuric acid (H2SO4) and subsequently 
compound 22 in MeOH/H2O was added dropwise, while maintaining the temperature at 
43°C. After complete addition the mixture was heated at 60°C for 1 h, thereafter it was 
heated at 70°C for 3 h. Excess MeOH was then added and the reaction mixture was refluxed 
for 6 h. The mixture was cooled in ice cold water, neutralised with 25% NH3, extracted with 
DCM and washed with H2O. The aqueous layer was then back extracted with DCM (× 3). 
The collected organic layers were dried over Na2SO4 and concentrated in vacuo. The crude 
material was purified by preparative thin layer chromatography with 95% DCM/MeOH as an 
eluent to give the desired product.    
4.11.1. Synthesis of N-3-bromophenyl-6-[2-(2,2-dimethoxyethoxy)ethoxy] 
pyrimidin-4-amine 41a 
 
The general procedure was followed using H2SO4 and compound 22a (87 mg, 0.229 mmol) 
in MeOH (3 mL) and H2O (1 mL). Thereafter MeOH (6 mL) was added. The crude material 
was purified by preparative thin layer chromatography with 95% DCM/MeOH as an eluent to 
yield compound 41a as a cream white solid (11.8 mg, 12%). m.p. = 100 – 101°C. 1H NMR 
(500 MHz, CDCl3) δ 8.35 (s, 1H, H-1’), 7.51 (s, 1H, H-6’), 7.24 – 7.20 (m, 3H, H-8’, H-9’ and 
H-10’), 6.93 (s, 1H, NH), 6.15 (s, 1H, H-3’), 4.52 (t, J = 5.2 Hz, 1H, H-4), 4.51 – 4.48 (m, 2H, 
H-1), 3.85 – 3.81 (m, 2H, H-2), 3.58 (d, J = 5.2 Hz, 2H, H-3), 3.39 (s, 6H, H-5). 13C NMR 
(125 MHz, CDCl3) δ 170.2 (C-2’), 161.7 (C-4’), 158.0 (C-1’), 139.9 (C-5’), 130.7 (C-9’), 127.4 
(C-8’), 124.7 (C-6’), 123.0 (C-7’), 120.4 (C-10’), 102.8 (C-4), 87.7 (C-3’), 71.0 (C-3),          
69.8 (C-2), 65.5 (C-1), 54.1 (C-5). IR (vmax./cm-1) 3316 (OH); 3242 (NH); 3081 (=C-H); 2742 
(-C-H); 1610 (–C=N); 1252 (=C-N); 1244 (alkoxy C-O). ESI-MS (m/z) calculated [M+H]+ for 
C16H21BrN3O4  398.0708, found 398.0710. 
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4.11.2. Synthesis of N-phenyl-6-[2-(2,2-dimethoxyethoxy)ethoxy] 
pyrimidin-4-amine 41b 
 
The general procedure was followed using H2SO4 and compound 22b (100 mg, 0.333 mmol) 
in MeOH (3 mL) and H2O (1 mL). Thereafter MeOH (6 mL) was added. The crude material 
was purified by preparative thin layer chromatography with 95% DCM/MeOH as an eluent to 
yield compound 41b as a cream white solid (27.8 mg, 25%). m.p. = 103 – 104°C. 1H NMR 
(400 MHz, CDCl3) δ 8.33 (s, 1H, H-1’), 7.37 (t, J = 7.8 Hz, 2H, H-6’), 7.29 – 7.27 (m, 2H,     
H-7’), 7.16 (t, J = 7.4 Hz, 1H, H-8’), 6.80 (s, 1H, NH), 6.15 (s, 1H, H-3’), 4.51 (t, J = 5.2 Hz, 
1H, H-4), 4.50 – 4.45 (m, 2H, H-1), 3.84 – 3.80 (m, 2H, H-2), 3.57 (d, J = 5.2 Hz, 2H, H-3), 
3.39 (s, 6H, H-5).  13C NMR (100 MHz, CDCl3) δ 170.6 (C-2’), 162.8 (C-4’), 158.5 (C-1’), 
137.9 (C-5’), 129.9 (C-7’), 125.3 (C-8’), 122.9 (C-6’), 103.3 (C-4), 87.4 (C-3’), 71.5 (C-3), 
70.3 (C-2), 65.8 (C-1), 54.5 (C-5). IR (vmax./cm-1) 3376 (OH); 3024 (NH); 2923 (=C-H); 2732 
(-C-H); 1625 (–C=N); 1248 (=C-N); 1235 (alkoxy C-O). ESI-MS (m/z) calculated [M+H]+ for 
C16H22N3O4  320.1608, found 320.1605. 
 
4.12. Synthesis of 6-chloro-4-(3-bromophenylamino)pyrimidine 26a 
 
Ethanol (100 mL), 3-bromoaniline 19a (6.9 g, 0.040 mol, 1 eq.) and triethylamine (5.6 mL, 
0.040 mol, 1 eq.) were sequentially added to a round bottomed flask containing 4,6-
dichloropyrimidine 18 (6.0 g, 0.040 mol, 1 eq.). The reaction was refluxed at 80°C for 18 h. 
After that the reaction was dissolved in EtOAc (50 mL) and consecutively washed with H2O 
(50 mL), saturated NH4Cl (50 mL) and brine (50 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give compound 26a as a yellow solid (6.3 g, 55%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.03 (s, 1H, NH), 8.55 (s, 1H, H-1’), 8.06 (s, 1H, H-6’), 7.57 – 
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7.51 (m, 1H, H-8’), 7.31 (t, J = 8.0 Hz, 1H, H-9’), 7.27 – 7.23 (m, 1H, H-10’), 6.84 (s, 1H, H-
3’). 13C NMR (75 MHz, DMSO) δ 160.9 (C-2’), 158.4 (C-4’), 158.0 (C-1’), 140.7 (C-5’), 130.7 
(C-9’), 125.5 (C-8’), 122.2 (C-6’), 121.6 (C-7’), 118.8 (C-10’), 105.7 (C-3’). 
4.13. Synthesis of 4-(3-bromophenylamino)-6-{2-[2-(tetrahydro-2H-pyran-
2-yloxy)ethoxy] ethoxy}pyrimidine 29a 
 
Method 1 
Sodium hydride (845 mg, 2.11 mmol, 1.2 eq.) was flame dried under vacuum and purged 
with N2 (g) three times. Dry DMF (4 mL) and 2-[2-((tetrahydropyranyloxy)ethoxy]ethanol 17 
(330 mg, 1.76 mmol, 1 eq.) were added and the reaction mixture was stirred for 40 min. After 
that, a solution of 6-chloro-4-(3-bromophenylamino)pyrimidine 26a (500 mg, 1.76 mmol, 1 
eq.) in DMF (4 mL) was cannulated to the reaction mixture. The reaction mixture was then 
stirred at 150°C for 24 h. The product was extracted using DCM (100 mL) and washed three 
times with water (50 mL) and once with brine (50 mL). The combined organic layers were 
dried over Na2SO4. The solvent was removed in vacuo and the crude material was purified 
by silica gel column chromatography with 95% DCM/MeOH as an eluent to give compound 
29a as a yellow solid (~30 mg, 3.9%). 
Method 2 
Alternatively, method 1 was followed using DMSO as a solvent to give compound 29a as a 
yellow solid (123 mg, 16%). 
Method 3 
Alternatively, Pd2(dba)3 (242 mg, 4 mol%) and (rac)-BINAP (494 mg, 12 mol%) were added 
to a round bottomed flask containing DMSO (15 mL). The flask was sealed and stirred at 
80°C for 10 min under nitrogen purge. 4-chloro-6-{2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy] 
ethoxy}pyrimidine 31 (2.00 g, 6.62 mmol, 1 eq.), 3-bromoaniline 19a (2.27 g, 13.3 mmol, 2 
eq.) and K2CO3 (915 mg, 6.62 mmol, 1 eq.) were then consecutively added and the reaction 
was stirred at 80°C overnight. The reaction mixture was dissolved in chloroform (200 mL) 
and washed twice with water (100 mL). The combined organic layers were dried over 
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Na2SO4. The solvent was removed in vacuo and the crude reddish-brown oil was purified by 
silica gel column chromatography with 50% EtOAc/Hex as an eluent to yield compound 29a 
as a yellow solid (580 mg, 20%).  
Method 4 
Method 3 was repeated using Pd2(dba)3 (54.0 mg, 2 mol%) and (rac)-BINAP (112 mg, 
6 mol%) which were added to a round bottomed flask containing DMSO (5 mL). Thereafter 
4-chloro-6-{2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]ethoxy}pyrimidine 31 (906 mg, 
3.00 mmol, 1 eq.), 3-bromoaniline 19a (1.03 g, 6.00 mmol, 2 eq.) and K2CO3 (415 mg, 
3.00 mmol, 1 eq.) were then consecutively added and the reaction was stirred at 80°C 
overnight. The crude reddish-brown oil was purified by silica gel column chromatography 
with 50% EtOAc/Hex as an eluent to yield compound 29a as a yellow solid (638 mg, 22%). 
1H NMR (300 MHz, CDCl3) δ 8.35 (s, 1H, H-1’), 7.51 (s, 1H, H-6’), 7.23 – 7.21 (m, 3H, H-8’, 
H-9’ and H-10’), 6.16 (s, 1H, H-3’), 4.66 – 4.60 (m, 1H, H-5), 4.52 – 4.46 (m, 2H, H-1),     
3.93 – 3.80 (m, 4H, H-2, H-4 and H-9), 3.76 – 3.69 (m, 2H, H-3), 3.67 – 3.58 (m, 1H, H-9), 
3.53 – 3.44 (m, 1H, H-4), 1.87 – 1.44 (m, 6H, H-6, H-7 and H-8). 
4.14. Synthesis of 4-(3-bromophenylamino)-6-dimethylaminopyrimidine 30a 
 
Sodium hydride (845 mg, 2.11 mmol, 1.2 eq.) was flame dried under vacuum and purged 
with N2(g) three times. Dry DMF (4 mL) and 2-[2-((tetrahydropyranyloxy)ethoxy]ethanol 17 
(330 mg, 1.76 mmol, 1 eq.) was added and the reaction mixture was stirred for 40 min. After 
that, a solution of 6-chloro-4-(3-bromophenylamino)pyrimidine 26a (500 mg, 1.76 mmol, 1 
eq.) in DMF (4 mL) was cannulated to the reaction mixture. The reaction mixture was then 
stirred at 150°C for 24 h. The product was extracted using DCM (100 mL) and washed three 
times with water (50 mL) and once with brine (50 mL). The combined organic layers were 
dried over Na2SO4. The solvent was removed in vacuo and crude material was purified by 
silica gel column chromatography with 95% DCM/MeOH as an eluent give compound 30a as 
a pale yellow solid (268 mg, 52%). 1H NMR (300 MHz, CDCl3) δ 8.26 (s, 1H, H-1’), 7.78 (s, 
1H, NH), 7.53 (s, 1H, H-6’), 7.26 – 7.16 (m, 3H, H-8’, H-9’ and H-10’), 5.83 (s, 1H, H-3’), 3.05 
(s, 6H, H-11’). 
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4.15.  Synthesis of 4-chloro-6-isopropoxypyrimidine 32 
 
Potassium bis(trimethylsilyl)amide (KHMDS) (5 mL) was added to a solution of 4-chloro-6-{2-
[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy] ethoxy}pyrimidine 31 (1.00 g, 3.31 mmol, 1 eq.) in 2-
propanol (80 mL). 3-Bromoaniline (854 mg, 4.97 mmol, 1.5 eq.) was then added and the 
reaction mixture was refluxed overnight. The solvent was removed in vacuo and crude 
material was purified by silica gel column chromatography with 94% DCM/MeOH as an 
eluent to give compound 32 as a white solid (170 mg, 30%). 1H NMR (300 MHz, CDCl3)          
δ 8.55 (s, 1H, H-1’), 6.71 (s, 1H, H-3’), 5.39 (hept, J = 6.3 Hz, 1H, H-1), 1.36 (d, J = 6.3 Hz, 
6H, H-2). 13C NMR (75 MHz, CDCl3) δ 169.9 (C-2’), 160.6 (C-4’), 158.2 (C-1’), 108.2 (C-3’), 
70.7 (C-1), 21.8 (C-2). 
4.16. Synthesis of 4-dimethylamino-6-{2-[2-(tetrahydro-2H-pyran-2-yloxy) 
ethoxy]ethoxy}pyrimidine 33 
 
Potassium bis(trimethylsilyl)amide (KHMDS) (2.5 mL) was added to a solution of 4-chloro-6-
{2-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy] ethoxy}pyrimidine 31 (500 mg, 1.66 mmol, 1 eq.) 
in DMF (15 mL). 3-Bromoaniline (185 mg, 1.99 mmol, 1.2 eq.) was then added and the 
reaction mixture was stirred at 80°C overnight. The product was extracted using DCM (100 
mL) and washed three times with water (50 mL) and once with brine (50 mL). The combined 
organic layers were dried over Na2SO4. The solvent was removed in vacuo and crude 
material was purified by silica gel column chromatography with 50% EtOAc/Hex as an eluent 
give compound 33 as a clear oil (274 mg, 46%). 1H NMR (300 MHz, CDCl3) δ 8.28 (s, 1H, 
H-1’), 5.77 (s, 1H, H-3’), 4.66 – 4.62 (m, 1H, H-5), 4.49 – 4.45 (m, 2H, H-1), 3.93 – 3.81 (m, 
4H, H-2, H-4 and H-9), 3.76 – 3.69 (m, 2H, H-3), 3.66 – 3.58 (m, 1H, H-9), 3.53 – 3.45 (m, 
1H, H-4), 3.06 (s, 6H, H-5’), 1.91 – 1.45 (m, 6H, H-6, H-7 and H-8). 
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APPENDIX 
 
A1. Docking protocol 
In order to investigate the potential binding modes that our pyrimidine ketoamides could 
have with wild type and T790M mutated EGFR, computational docking was done using 
CDOCKER (Discovery Studio 4.0). The protein X-ray crystal structure of the T790M mutated 
EGFR (PDB code: 4I24) was downloaded from the protein data bank (PDB). The protein 
PDB file was prepared for docking by firstly checking and adjusting the tautomeric state of 
each Histidine residue to maximize H-bonding, and H-bonds added to the rigid model 
followed by protein minimization. Minimization was performed on the protein model using the 
CHARMm force field Smart Minimizer algorithm. This was done by performing 20000 steps 
of steepest decent (with RMS gradient tolerance of 0.01 kcal/mol) in a Generalized Born with 
a simple Switching (GBSW) implicit solvent model (pH 7.4). This was followed by a 
conjugate Gradient minimization step. 
 The reliability of the CDOCKER protocol and parameters was first verified by docking the X-
ray crystal structure ligands erlotinib and dacomitanib back into the active site of the T790M 
(PDB: 4I24) EGFR. Encouragingly, the top ranked docked poses for each ligand compared 
favorably with the X-ray crystal bound structures suggesting the docking parameters used 
were reliable. We then proceeded to dock our proposed pyrimidine ketoamide library with 
the T790M EGFR. The pyrimidine ketoamides were built in ChemDraw 12 and subsequently 
exported into Discovery Studio (DS) for docking. They were first prepared for docking using 
the prepare ligand protocol and then energy minimized using DS.  
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A2. Selected 1H and 13C NMR spectra 
 
A2.1. Compound 17 
 
 
1H NMR spectrum  
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13C NMR spectrum  
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A2.2. Compound 18 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.3. Compound 31 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.4. Compound 34 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.5. Compound 26a 
 
 
1H NMR spectrum 
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13C NMR spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
 
 
A2.6. Compound 16e 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.7. Compound 16f 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.8. Compound 15e 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.9. Compound 14e 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.10. Compound 13b 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.11. Compound 22a 
 
 
1H NMR spectrum 
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13C NMR spectrum 
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A2.12. Compound 41b 
 
1H NMR spectrum 
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